

(19)



(11)

EP 1 032 269 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
29.08.2007 Bulletin 2007/35

(51) Int Cl.:
A01N 63/00 (2006.01) A61K 35/76 (2006.01)
C12N 7/00 (2006.01) C12N 7/02 (2006.01)

(21) Application number: **98949797.9**

(86) International application number:
PCT/US1998/021230

(22) Date of filing: **09.10.1998**

(87) International publication number:
WO 1999/018799 (22.04.1999 Gazette 1999/16)

(54) **TREATMENT OF NEOPLASMS WITH INTERFERON-SENSITIVE, CLONAL VIRUSES**

BEHANDLUNG VON NEOPLASMEN MIT INTERFERON-EMPFINDLICHEN, KLONALEN VIREN

TRAITEMENT DE NEOPLASMES PAR DES VIRUS CLONÉS SENSIBLES A L'INTERFERON

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **09.10.1997 US 948244**

(43) Date of publication of application:
06.09.2000 Bulletin 2000/36

(73) Proprietor: **Wellstat Biologics Corporation**
Gaithersburg, MD 20878 (US)

(72) Inventors:
• **ROBERTS, Michael, S.**
Walkersville, MD 21793 (US)
• **LORENCE, Robert, M.**
Bethesda, MD 20817 (US)
• **GROENE, William, S.**
New Market, MD 21774 (US)
• **RABIN, Harvey**
Rockville, MD 20852 (US)
• **VON BORSTEL, Reid, W.**
Potomac, MD 20854 (US)

(74) Representative: **MacLean, Martin Robert et al**
Mathys & Squire
120 Holborn
London EC1N 2SQ (GB)

(56) References cited:
WO-A-94/19022 WO-A-96/26285

• **SINKOVICS J. ET AL: "New developments in the
virus therapy of cancer: A historical review."
INTERVIROLOGY, (1993) 36/4 (193-214).,
XP000982845**

• **HORVATH J ET AL: "Comparison of oncolytic
Newcastle disease virus strains."
PROCEEDINGS OF THE AMERICAN
ASSOCIATION FOR CANCER RESEARCH
ANNUAL, vol. 36, 1995, page 439 XP002164069
Eighty-sixth Annual Meeting of the American
Association for Cancer Research; Toronto,
Ontario, Canada; March 18-22, 1995, 1995 ISSN:
0197-016X**

• **RESTIFO N P ET AL: "A NONIMMUNOGENIC
SARCOMA TRANSDUCED WITH THE CDNA FOR
INTERFERON GAMMA ELICITS CD8-POSITIVE T
CELLS AGAINST THE WILD-TYPE TUMOR
CORRELATION WITH ANTIGEN PRESENTATION
CAPABILITY" JOURNAL OF EXPERIMENTAL
MEDICINE, vol. 175, no. 6, 1992, pages 1423-1431,
XP000990661 ISSN: 0022-1007**

• **BEATTIE ELIZABETH ET AL: "Host-range
restriction of vaccinia virus E3L-specific deletion
mutants." VIRUS GENES, vol. 12, no. 1, 1996,
pages 89-94, XP000990662 ISSN: 0920-8569**

• **ARROYO P J ET AL: "ACTIVE SPECIFIC
IMMUNOTHERAPY WITH VACCINIA COLON
ONCOLYSATE ENHANCES THE
IMMUNOMODULATORY AND ANTITUMOR
EFFECTS OF INTERLEUKIN-2 AND INTERFERON
ALPHA IN A MURINE HEPATIC METASTASIS
MODEL" CANCER IMMUNOLOGY
IMMUNOTHERAPY, vol. 31, no. 5, 1990, pages
305-311, XP000990671 ISSN: 0340-7004**

• **YU ZHONG ET AL: "Antiviral action of interferon-
beta on Newcastle disease virus: Selectivity to
the hemagglutinin-neuraminidase gene
expression." MEDICAL MICROBIOLOGY AND
IMMUNOLOGY, vol. 184, no. 1, 1995, pages 45-52,
XP000990658 ISSN: 0300-8584**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 032 269 B1

- DATABASE CAPLUS ON STN, (Columbus, Ohio, USA);CHEMICAL ABSTRACT SERVICE, DN 116: 104333, ZHENG B., "Attenuated NewCastle Disease Virus for Induction of Interferons to Combat Neoplasm or Viral Diseases", XP002915850; & CN 1054192 A (09 April 1991).
- GRESSER et al., "Exogenous Interferon and Inducers of Interferon in the Treatment of Balb/c Mice Inoculated with RC19 Tumor Cells", NATURE, 23 August 1969, Vol. 223, pages 844-845, XP002915851

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description**Field of the Invention**

- 5 [0001] The subject invention relates to clonal viruses that are able to replicate in and cause the death of neoplastic cells with a deficiency in the interferon (IFN)-mediated antiviral response. RNA and DNA viruses are useful in this regard. The invention also relates to the use of these viruses for the treatment of neoplastic diseases including cancer and large tumors.

10 **Background of the Invention**

- [0002] Neoplastic disease which includes cancer is one of the leading causes of death among human beings. There are over 1.3 million new cases of cancer diagnosed in the United States each year and 550,000 deaths. Detecting cancer early, before it has spread to secondary sites in the body, greatly increases a host's chances of survival. However, early detection of cancer is not always possible, and even when it is, treatments are unsatisfactory, especially in cases of highly malignant cancers. Cancer treatments, including chemotherapy and radiation, are much less effective in latter stages, especially when neoplastic growths are large and/or constitute a high tumor burden. (See Hillard Stanley, Cancer Treat. Reports, Vol. 61, No. 1, Jan/Feb 1977, p.29-36, Tannock, Cancer Research, 42, 4921-4926, Dec. 1982).

- 15 [0003] Tumor regression associated with exposure to various viruses has been reported. Most of the viruses described are pathogenic in humans, and include mumps and measles. The effect of other specific viruses on particular types of cancer cells has also been described. Smith et al, (1956) Cancer, 9, 1211 (effect of adenovirus on cervix carcinoma); Holzaepfel et al, (1957) Cancer, 10, 557 (effect of adenovirus on epithelial tumor); Taylor et al, (1970) J. Natl. Cancer Inst., 44, 515 (effect of bovine enterovirus-1 on sarcoma-1); Shingu et al, (1991) J. General Virology, 72, 2031 (effect of bovine enterovirus MZ-468 on F-647a leukemia cells); Suskind et al, (1957) PSEBM, 94, 309 (effect of coxsackie B3 virus on HeLa tumor cells); Rukavishnikova et al, (1976) Acta Virol., 20, 387 (effect of influenza A strain on ascites tumor).

- 20 [0004] The earliest references described partial tumor regression in patients treated with live attenuated viral vaccine with the aim to vaccinate them against smallpox or rabies. See DePace, N.G. (1912) Ginecologia, 9, 82-88; Salmon, P. & Baix (1922) Compt. Rend. Soc. Biol., 86, 819-820. Partial regression of tumors and regression of leukemias have also been noted during naturally occurring measles infections. See Pasquinucci, G. (1971) Lancet, 1, 136; Gross, S. (1971) Lancet, 1, 397-398; Bluming, A.Z. and Ziegler, J.L. (1971) Lancet, 2, 105-106. In one study of 90 cancer patients intentionally infected with live mumps virus, partial tumor regression was noted in 79 cases. See Asada (1994) Cancer, 34, 1907-1928. While the side effects of these viruses were temporary, serious sequela of infection with these human pathogens is of major concern.

- 25 [0005] Viruses are categorized as follows [see Murphy A and Kingsbury DW, 1990, In: Virology, 2nd Edition (Ed. Fields, B.N.), Raven Press, New York, pp 9-35]:

	Dividing Characteristics	Virus Family Names
	RNA viruses	
40	ssRNA. positive-sense, nonsegmented, nonenveloped,	<i>Picomaviridae, Calciviridae</i>
	ssRNA, positive-sense, nonsegmented, enveloped,	<i>Togaviridae, Flaviviridae, Coronaviridae</i>
45	ssRNA. negative-sense, nonsegmented, enveloped,	<i>Rhabdoviridae, Filoviridae, Paramyxoviridae</i>
	ssRNA. negative-sense, segmented, enveloped	<i>Orthomyxoviridae</i>
50	ssRNA. ambisense, segmented, enveloped	<i>Bunyaviridae, Arenaviridae</i>
	dsRNA. positive-sense segmented, nonenveloped	<i>Reoviridae, Birnaviridae</i>
55	ssRNA. DNA step in	<i>Retroviridae</i>

(continued)

	Dividing Characteristics	Virus Family Names
	RNA viruses	
5	replication, positive-sense, nonsegmented, enveloped	
	DNA viruses	
	ss/dsDNA, nonenveloped	<i>Hepadnaviridae</i>
10	ssDNA, nonenveloped	<i>Parvoviridae</i>
	dsDNA, nonenveloped	<i>Papovaviridae, Adenoviridae</i>
	dsDNA, enveloped	<i>Herpesviridae, Poxviridae, Iridoviridae</i>
15	[0006] Included among the family Herpesviridae (or Herpesviruses), are the subfamilies Alphaherpesvirus (including Genus Varicellavirus and Genus Simplexvirus), Betaherpesvirus, and Gammaherpesvirus.	
20	[0007] Newcastle disease virus ("NDV") is a member of the Paramyxoviridae (or Paramyxoviruses). The natural hosts for NDV are chickens and other birds. NDV typically binds to certain molecules on the surface of animal host cells, fuses with the cell surface, and injects its genetic material into the host. NDV is a cytocidal virus. Once inside the cell, the viral genes direct the host cell to make copies of the virus leading to death of the host cell, releasing the copies of NDV which infect other cells. Unlike some viruses, NDV is not known to cause any serious human disease. Unlike other kinds of viruses (e.g., HTLV-1, Hepatitis B), Paramyxoviruses are not known to be carcinogenic.	
25	[0008] Temporary regression of tumors has been reported in a small number of patients exposed to NDV. See, Csatory, L.K. (1971) Lancet, 2, 825. Csatory noted the regression of a gastrointestinal cancer in a chicken farmer during an epidemic of Newcastle disease in his chickens. In a similar anecdotal report, Cassel, W.A. and Garrett, R.E. (1965) Cancer, 18, 863-868. noted regression of primary cervical cancer, which had spread to the lymph nodes, in a patient following injection of NDV into the cervical tumor. Since the mechanism of tumoricidal activity was thought to be immunologic, no work was carried out to address direct tumor cytotoxicity of the virus. Instead, efforts focused upon the immunomodulating effects of NDV. See, for example, Murray, D.R., Cassel, W.A., Torbin, A.H., Olkowski, Z.L., & Moore, M.E. (1977) Cancer, 40, 680; Cassel, W.A., Murray, D.R., & Phillips, H.S. (1983) Cancer, 52, 856; Bohle, W., Schlag, P.J., Liebrich, W., Hohenberger, P., Manasterski, M., Miller, P., and Schirmacher, V. (1990) Cancer, 66, 1517-1523.	
30	[0009] The selection of a specific virus for tumor regression was based on serendipity or trial and error in the above citations. Only recently, have rational, mechanism-based approaches for virus use in cancer treatment been developed using DNA viruses. Examples of this type of approach are found in the development of recombinant adenoviral vectors that replicate only in tumors of specific tissue origin (Rodriguez, R. et al, 1997 Cancer Res., 57:2559-2563), or those that lack certain key regulatory proteins (Bischoff, J.R. et al, 1996 Science, 274:373-376). Another recent approach has been the use of a replication-incompetent recombinant adenoviral vector to restore a critical protein function lost in some tumor cells (Zhang, WW, et al, 1994 Cancer gene therapy, 1:5-13). Finally, herpes simplex virus has also been engineered to replicate preferentially in the rapidly dividing cells that characterize tumors (Mineta, T., et al, 1994 Cancer Res., 54: 3963-3966).	
40	[0010] WO 94/25627, discloses the use of NDV or other Paramyxovirus in the treatment of cancer.	

Viral IFN transgene expression

45	[0011] One common approach to the treatment of cancer with viral therapeutics has been the use of virus vectors for the delivery of certain genes to the tumor mass.	
	[0012] Recombinant adenovirus, adeno-associated virus, vaccinia virus and retroviruses have all been modified to express an interferon gene alone or in combination with other cytokine genes.	
50	[0013] In Zhang et al. ((1996) Proc. Natl. Acad. Sci., USA 93:4513-4518), a recombinant adenovirus expressing a human interferon consensus (i.e., synthetic) gene was used to treat human breast cancer (and other) xenografts in nude mice. The authors concluded "...a combination of viral oncolysis with a virus of low pathogenicity, itself <i>resistant</i> to the effects of IFN and IFN gene therapy, might be a fruitful approach to the treatment of a variety of different tumors, in particular breast cancer. "In contrast to subject invention which relates to interferon-sensitive viruses, Zhang et al. (1996) teach the use of an interferon-resistant adenovirus in the treatment of tumors.	
55	[0014] In Zhang et al. ((1996) Cancer Gene Ther., 3:31-38), adeno-associated virus (AAV) expressing consensus IFN was used to transduce human tumor cells in vitro followed by injection into nude mice. The transduced tumors either did not form tumors or grew slower than the non-transduced controls. Also, injection of one transduced human tumor cell into the tumor mass of another, non-transduced tumor resulted in a small decrease in size.	

[0015] In Peplinski et al. ((1996) Ann. Surg. Oncol., 3:15-23), IFN gamma (and other cytokines, expressed either alone, or in combination) were tested in a mouse breast cancer model. Mice were immunized with tumor cells virally modified with recombinant vaccinia virus. When rechallenged with tumor cells, the mice immunized with virally modified cells had statistical improvement in the disease-free survival time.

5 [0016] Gastl, et al. ((1992) Cancer Res., 52:6229-6236), used IFN gamma-expressing retroviral vectors to transduce renal carcinoma cells in vitro. These cells were shown to produce higher amounts of a number of proteins important for the function of the immune system.

[0017] Restifo et al. ((1992) J. Exp. Med., 175:1423-1431), used IFN gamma-expressing retroviral vector to transduce a murine sarcoma cell line allowing the tumor cell line to more efficiently present viral antigens to CD8+ T cells.

10 [0018] Howard, et al. ((1994) Ann. NY Acad. Sci., 716:167-187), used IFN gamma-expressing retroviral vector to transduce murine and human melanoma tumor cells. These cells were observed to increase the expression of proteins important to immune function. These cells were also less tumorigenic in mice as compared to the non-transduced parent line, and resulted in activation of a tumor-specific CTL response in vivo.

15 Use of Therapeutic Doses of Interferon as an Adjuvant to Viral Cancer Therapy

[0019] Because of the known immune-enhancing properties of IFN, several studies have examined the use of IFN protein in combination with other viral cancer vaccine therapies.

20 In Kirchner et al. ((1995) World J. Urol., 13:171-173), 208 patients were immunized with autologous, NDV-modified, and lethally irradiated renal-cell carcinoma tumor cells, and were co-treated with low dose IL-2 or IFN alpha. The authors stated that this treatment regime results in an improvement over the natural course in patients with locally-advanced renal-cell carcinoma. The dose was approximately 3.3×10^3 to 2.2×10^5 PFU/kg. This was a local therapy, as opposed to a systemic approach, with the goal of inducing an anti-tumor immune response.

25 [0020] Tanaka et al. ((1994) J. Immunother. Emphasis Tumor Immunol, 16:283-293), co-administered IFN alpha with a recombinant vaccinia virus as a cancer vaccine therapy model in mice. This study showed a statistical improvement in survivability in mice receiving IFN as compared to those that did not. The authors attributed efficacy of IFN to the induction of CD8-positive T cells in those animals.

[0021] Arroyo et al. ((1990) Cancer Immunol, Immunother., 31:305-311) used a mouse model of colon cancer to test the effect of IFN alpha and/or IL-2 co-therapy on the efficacy of a vaccinia virus colon oncolysate (VCO) cancer treatment.

30 They found that the triple treatment of VCO+IL-2+IFN was most efficacious in this murine model. This approach relies on immunization as the mechanism of anti-tumor activity

[0022] IFN was used in these studies to augment the ability of the cancer cells to be recognized by the immune system.

[0023] Intervirology (1993) 36/4 (193-214) provides a review of virus therapies for cancer.

35 [0024] Proceedings of the American Association for Cancer Research Annual, Vol 36, 1995, page 439, provides a comparison of oncolytic Newcastle Disease Virus strains.

[0025] WO 96/26285 describes methods and compositions for administering gene therapy vectors.

[0026] DChemical Abstract Service, DN 116:104333, & CN 1054192 A describes a process for preparing inducing interferon of human body.

40 [0027] Nature, 23 August 1969, Vol. 223, pgs 844-845 describes exogenous interferon and inducers of interferon in the treatment of Balb/c mice inoculated with RC19 tumour cells.

[0028] It is an object of the invention to provide viruses for the treatment of diseases including cancer. It is a further object of the invention to provide viruses for the treatment of neoplastic diseases including cancer.

It is a further object of the invention to provide a means by which candidate viruses are selected and/or screened for use in the therapy of neoplastic diseases.

45 It is a further object of the invention to provide guidance in the genetic engineering of viruses in order to enhance their therapeutic utility in the treatment of neoplastic diseases.

It is a further object of this invention to provide a means with which to screen potential target cells for viral therapy with the goal of assessing the sensitivity of the candidate target cells to viral killing.

It is a still further object of this invention to provide guidance in the management of viral therapy:

50 It is an object of the invention to provide for treating large tumours.

It is a further object of the invention to provide purified virus and methods for obtaining same.

[0029] The present invention provides use of an interferon-sensitive, replication-competent clonal RNA virus for the manufacture of a medicament for treating a neoplasm in a mammal.

55 [0030] This invention thus relates to infecting a neoplasm in a mammal with a virus comprising the use of an interferon-sensitive, replication-competent clonal virus, selected from the group consisting of RNA viruses and the DNA virus families of Adenovirus, Parvovirus, Papovavirus and Iridovirus, for the manufacture of a medicament.

[0031] This invention also relates to infecting a neoplasm in a mammal with a virus comprising systemically administering an interferon-sensitive, replication-competent clonal virus to the mammal.

[0032] This invention also relates to treating a neoplasm including cancer in a mammal comprising the use of a therapeutically effective amount of an interferon-sensitive, replication-competent, clonal virus selected from the group consisting of RNA viruses, and the DNA virus families of Adenovirus, Parvovirus, Papovavirus and Iridovirus, for the manufacture of a medicament.

5 [0033] This invention also relates to a method of infecting a neoplasm in a mammal with a virus comprising the use of an interferon-sensitive, replication-competent clonal vaccinia virus, having one or more mutations in one or more viral genes involved with blocking interferon's antiviral activity selected from the group of genes consisting of K3L, E3L and B 18R, for the manufacture of a medicament.

[0034] The invention also relates to the use, for the manufacture of a medicament for treating a neoplasm including cancer in a mammal, of a therapeutically effective amount of an interferon-sensitive, replication-competent vaccinia virus having one or more mutations in one or more viral genes involved with blocking interferon's antiviral activity selected from the group of genes consisting of K3L, E3L and B18R.

[0035] The invention also relates to infecting a neoplasm at least 1 cm in size with a virus in a mammal comprising the use of a clonal interferon-sensitive virus, selected from the group consisting of (1) RNA viruses; (2) Hepadenavirus; (3) Parvovirus; (4) Papovavirus; (5) Poxvirus; and (6) Iridovirus, for the manufacture of a medicament.

15 [0036] The invention also relates to the use, for the manufacture of a medicament for treating a neoplasm in a mammal, of a therapeutically effective amount of a clonal interferon-sensitive virus, selected from the group consisting of (1) RNA viruses; (2) Hepadenavirus; (3) Parvovirus; (4) Papovavirus; (5) Poxvirus; and (6) Iridovirus, wherein the neoplasm is at least 1 centimeter size.

20 [0037] The invention also relates to the use, for the manufacture of a medicament for treating a tumor in a mammal, of a therapeutically effective amount of an interferon-sensitive clonal RNA virus cytotoxic to the tumor, wherein the mammal has a tumor burden comprising at least 1.5% of the total body weight.

[0038] The invention also describes a method of screening tumor cells or tissue freshly removed from the patient to determine the sensitivity of the cells or tissue to killing by a virus comprising subjecting the cells or tissue to a differential cytotoxicity assay using an interferon-sensitive virus.

25 [0039] The invention also describes a method for identifying a virus with antineoplastic activity in a mammal comprising a) using the test virus to infect i) cells deficient in IFN-mediated antiviral activity, and ii) cells competent in IFN-mediated antiviral activity, and b) determining whether the test virus kills the cells deficient in IFN-mediated antiviral activity preferentially to the cells competent in interferon-mediated antiviral activity.

30 [0040] The invention also describes a method of making viruses for use in antineoplastic therapy comprising: a) modifying an existing virus by diminishing or ablating a viral mechanism for the inactivation of the antiviral effects of IFN, and optionally b) creating an attenuating mutation that results in lower virulence than said existing virus.

[0041] The invention also describes a method of controlling viral replication in a mammal treated with a virus selected from the group consisting of RNA viruses, Adenoviruses, Poxviruses, Iridoviruses, Parvoviruses, Hepadnaviruses, and Varicellaviruses, comprising administering an antiviral compound.

35 [0042] This invention also relates to treating or infecting a neoplasm in a mammal comprising subjecting a sample (e.g., serum, tumor cells, tumor tissue, tumor section) from the mammal to an immunoassay to detect the amount of virus receptor present to determine if the neoplasm will allow the virus to bind and cause cytolysis, and if the receptor is present, using an interferon-sensitive, replication competent clonal virus, which binds the receptor, for the manufacture of a medicament.

40 [0043] The invention also relates to infecting a neoplasm in a mammal with a virus comprising systemically administering a desensitizing dose of an interferon-sensitive, replication-competent clonal virus to the mammal.

[0044] The invention also relates to infecting a neoplasm in a mammal with a virus comprising administering an interferon-sensitive, replication-competent clonal virus to the mammal over a course of at least 4 minutes.

45 [0045] This invention also relates to infecting a neoplasm in a mammal with a virus comprising administering a replication-competent clonal virus selected from the group consisting of the Newcastle disease virus strain MK107, Newcastle disease virus strain NJ Roakin, Sindbis virus, and Vesicular stomatitis virus.

[0046] Included in the invention are:

- 50 1) a Paramyxovirus purified by ultracentrifugation without pelleting;
 ii) a Paramyxovirus purified to a level of at least 2×10^9 PFU per mg of protein;
 iii) a Paramyxovirus purified to a level of at least 1×10^{10} PFU per mg of protein;
 iv) a Paramyxovirus purified to a level of at least 6×10^{10} PFU per mg of protein;
 v) an RNA virus purified to a level of at least 2×10^9 PFU per mg of protein;
 55 vi) an RNA virus purified to a level of at least 1×10^{10} PFU per mg of protein;
 vii) an RNA virus purified to a level of at least 6×10^{10} PFU per mg of protein;
 viii) a cytotoxic DNA virus which is interferon-sensitive and purified to a level of at least 2×10^9 PFU/mg protein;
 ix) a replication-competent vaccinia virus having a) one or more mutations in one or more of the K3L, E3L and B18R

genes, and b) an attenuating mutation in one or more of the genes encoding thymidine kinase, ribonucleotide reductase, vaccinia growth factor, thymidylate kinase, DNA ligase, dUTPase;

x) a replication-competent vaccinia virus having one or more mutations in two or more genes selected from the group consisting of K3L, E3L, and B18R;

xi) a Herpesvirus having a modification in the expression of the (2'-5')A analog causing the Herpesvirus to have increased interferon sensitivity; and

xii) a Reovirus having an attenuating mutation at omega 3 causing said virus to become interferon-sensitive.

[0047] Also included in the invention are the following methods:

i) a method of purifying an RNA virus comprising the steps of a) generating a clonal virus; and b) purifying said clonal virus by ultracentrifugation without pelleting; or c) purifying said clonal virus by tangential flow filtration with or without subsequent gel permeation chromatography, and

ii) a method of purifying a Paramyxovirus comprising purifying the virus by ultracentrifugation without pelleting, or by tangential flow filtration with or without subsequent gel permeation chromatography.

[0048] The invention also relates to treating a disease in a mammal, in which the diseased cells have defects in an interferon-mediated antiviral response, comprising administering to the mammal a therapeutically effective amount of an interferon-sensitive, replication-competent, clonal virus.

Brief Description of the Drawings

[0049]

Figure 1 shows the effect of anti-interferon-beta antibody on viral antigen expression and infectious titer in NHEK (normal human epithelial keratinocytes) cells.

Figure 2 shows the effect of interferon-beta on viral antigen expression in different cells (normal human skin fibroblasts CCD922-sk and two types of head and neck carcinoma cells (KB and Hep2 cells).

Figure 3A shows the effect of interferon on viral antigen expression in CCD922-sk cells, and

Figure 3B shows the effect of interferon on viral antigen expression in KB cells.

Figure 4 shows the survival curves for athymic mice bearing human ES-2 ovarian carcinoma cells and treated with either saline or NDV strain PPMK107.

Figure 5 shows the interferon responsiveness of a number of human tumor and normal cell lines.

Detailed Description of the Invention

[0050] The present invention relates to the discovery of a novel mechanism by which viral replication selectively kills neoplastic cells deficient in an interferon (IFN)-mediated anti-viral response. This invention also provides methods for selection, design, purification, and use of viruses for the treatment of neoplastic diseases including cancer and large tumors. The viruses of the invention selectively replicate in and kill neoplastic cells based on the selective deficiency in these cells of an IFN-mediated anti-viral response. Administration of the appropriate dosage of virus results in neoplastic cell death, whereas normal cells, which possess an intact IFN-mediated anti-viral response, limit the replication of the virus and are not killed.

[0051] Included in the subject of the invention is the use of paramyxoviruses such as NDV, and other viruses, for use in the treatment of diseases including neoplastic disease such as cancer. The invention also teaches screening and engineering of other viruses suitable for use as therapeutics of neoplastic diseases. Another embodiment of the invention involves a method of identifying tumor tissues that are candidates for viral therapy. Finally, the invention also describes the preparation of highly purified virus.

Rationale for the use of interferon-sensitive viruses including NDV to treat neoplastic disease**NDV demonstrates selective killing of tumor cells.**

5 **[0052]** Newcastle disease virus causes selective cytotoxic effects against many human tumor cells with markedly less effects on most normal human cells. In a differential cytotoxicity assay, human cancer cells derived from sarcomas, melanomas, breast carcinomas, ovarian carcinomas, bladder carcinomas, colon carcinoma, prostate carcinoma, small cell and non-small cell lung carcinomas, and glioblastomas were discovered to be approximately 3 to 4 orders of magnitude more sensitive to NDV than many normal human cells [renal epithelial cells, fibroblasts, keratinocytes, melanocytes, and endothelial cells (see Example 1)]. The differential cytotoxicity assay can also be applied to fresh isolates from the patient's cells or tumor tissue.

10 **[0053]** An in vitro assay is used to define the tumoricidal activity of NDV as described in Example 1. The assay measures the amount of virus required to kill 50% of the tested cell culture in a five day time period. Examples 2 and 3 show the results of in vivo experiments in which virus was administered to athymic mice bearing human tumor xenografts by either the intratumoral (Example 2) or intravenous (Example 3) route. These results demonstrate that NDV can cause regression of a variety of human tumor types in a standard animal model for the testing of potential chemotherapeutic agents.

15 **[0054]** Evidence that NDV is specifically replicating within the tumor was demonstrated by immunohistochemical staining for virus antigen (Example 2). Within 30 minutes of intratumoral virus injection, the tumor tissue was negative for viral antigen. However, by day 2 post treatment, intense immunostaining for viral antigen was seen within the tumor, indicating virus replication within the tumor. Importantly, virus replication was specific for the tumor tissue since the neighboring connective tissue and skin was negative for viral antigen.

20 **[0055]** Importantly, efficient replication of NDV is crucial for the ability of the virus to kill infected cells, as demonstrated in studies using UV-inactivated non-clonal virus (Lorence, R., et al, 1994 J Natl Cancer Inst, 86:1228-1233).

25 **[0056]** NDV can also cause regression of large tumors after intratumoral and intravenous administration (Examples 4 through 9). Intratumoral NDV treatment of large intradermal A375 human melanoma xenografts (≥ 10 mm in maximal dimension; tumor volume of ≥ 300 mm³) in athymic mice lead to high rates of tumor regression (Examples 4 through 8). Intravenous NDV treatment of large subcutaneous HT1080 human fibrosarcoma xenografts (≥ 10 mm in maximal dimension) in athymic mice lead to complete or partial tumor regression in five out of six mice (Example 9).

30

The class I interferon family of cytokines are important negative modulators of viral infection.

35 **[0057]** The class I interferons consist of the IFN α , found primarily in cells of hematopoietic origin, and IFN β found primarily in fibroblasts and epithelial cells. [Joklik, W.K. 1990. Interferons. pp 383-410. Virology, second edition, edited by B.N. Fields, D.M. Knipe et al, Raven Press Ltd., New York; and Sreevalsan, T. 1995. Biological Therapy with Interferon- α and β : Preclinical Studies. pp 347-364. Biologic Therapy of Cancer, second edition, edited by V.T. DeVita, Jr., S. Hellman, and S.A. Rosenberg, J.B. Lippincott Company, Philadelphia.] Both types of IFN function through an apparently common mechanism of action that includes the degradation of double-stranded RNA intermediates of viral replication, and the inhibition of cellular translation through the activity of a protein kinase activated by double-stranded RNA (Joklik, W.K. 1990. Interferons. pp 383-410. Virology. Second Edition, edited by B.N. Fields, D.M. Knipe et al., Raven Press Ltd., New York; and references therein). Several viruses (influenza, EBV, SV40, adenovirus, vaccinia) have evolved mechanisms by which one or more pathways of the IFN system are inactivated, thus allowing the efficient replication of the virus (Katze, M.G. 1995. Trends in Microbiol. 3:75-78).

45 **A wide variety of tumor cells are deficient in the ability to limit viral infection through an IFN-dependent mechanism.**

50 **[0058]** Human cervical carcinoma cells (HeLa) were over three-hundred-fold less sensitive to the inhibition of vesicular stomatitis virus replication following pre-treatment with IFN than a non-transformed fibroblast control cell line (Maheshwari R.K., 1983. Biochem, Biophys. Res. Comm. 17:161-168). The subject inventors have discovered that infection of a co-culture of tumorigenic human head and neck carcinoma cells (KB) and normal human skin fibroblast cells (CCD922-sk) results in viral replication initially in both cell types, followed by a limiting of the infection in the normal cells versus continued replication and killing of the tumor cells (Example 10). Moreover, although IFN was being secreted by the normal cells into the culture medium, the tumor cells were unable to respond to the IFN at the concentrations being produced to establish an antiviral state. Further evidence for the role of IFN in the differential sensitivity of tumor cells versus normal cells to killing by NDV was obtained in two separate experiments in which normal fibroblast cells (CCD922-sk) or normal epithelial keratinocyte cells (NHEK) were shown to become more sensitive to infection with NDV in the presence of neutralizing antibody to IFN (Examples 11 and 12). Finally, parallel infection of normal fibroblasts (CCD922-

55

sk) and human tumor cells (KB) in the presence of IFN revealed that the normal cells were at least 100-fold more sensitive to the antiviral effects of added IFN than were the tumor cells (Examples 13 and 14). Similar testing of variety tumor cell lines (total of 9) revealed a clear correlation in the relative sensitivity of a cell line to killing by NDV and an inability of the cell line to manifest an interferon-mediated antiviral response (Example 26).

Interferon and Cell Growth

[0059] There are several species of interferon (IFN) including natural and recombinant forms of α -IFN, β -IFN, ω -IFN, and γ -IFN as well as synthetic consensus forms (e.g., as described in Zhang et al. (1996) *Cancer Gene Therapy*, 3: 31-38). In addition to the anti-viral activities that lead to its discovery, IFN is now known to play an important role in the normal regulation of cell growth and differentiation. IFN is viewed as a negative growth regulator and several key proteins involved in the function and regulation of IFN activity have been shown to act as tumor-suppressor proteins in normal cells (Tanaka et al, 1994 *Cell* 77:829-839). Moreover, several other proteins known to antagonize the anti-viral activity of IFN have been shown to have oncogenic potential when expressed inappropriately (see below, Barber, GN, 1994, *Proc. Natl. Acad. Sci USA* 91:4278-4282). Cells derived from a number of human cancers have been shown to be deleted in the genes encoding IFN (James, CD, et al, 1991, *Cancer Res.*, 51:1684-1688), and partial or complete loss of IFN function has been observed in human cervical carcinoma (Petricoin, E, et al, 1994 *Mol. Cell. Bio.*, 14:1477-1486), chronic lymphocytic leukemia (Xu, B., et al, 1994, *Blood*, 84:1942-1949), and malignant melanoma cells, (Linge, C., et al, 1995, *Cancer Res.*, 55:4099-4104).

[0060] The IFN-inducible protein kinase (p68) has been shown to be an important regulator of cellular and viral protein synthesis. A correlation has emerged that links the expression or activity of the p68 kinase to the cellular state of differentiation. Thus, poorly differentiated cells, such as those occurring in many cancers, are deficient in p68 function (Haines, G.K., et al, 1993 *Virchows Arch B Cell Pathol.* 63:289-95). Cells that lack p68 activity are generally sensitive to viral mediated killing because the p68 kinase is an important effector of the IFN-inducible antiviral state. The antiviral activity of p68 can be antagonized through a direct interaction with a cellular protein identified as p58. When cloned and overexpressed in NIH3T3 cells, p58 causes the cells to exhibit a transformed phenotype and anchorage-independent growth (Barber GN et al., 1994 *Proc Natl Acad Sci USA* 91:4278-4282), and a number of human leukemia cell lines have been shown to overexpress the p58 protein (Korth MJ, et al., 1996 *Gene* 170:181-188). Sensitivity to viral killing in undifferentiated cells can be reversed through the induction of a more differentiated phenotype (Kalvakolanu, DVR and Sen, G.C. 1993 *Proc Natl Acad Sci USA* 90:3167-3171).

Definitions

[0061] Cells competent in an interferon-mediated antiviral response. As used herein, the term "cells competent in an interferon-mediated antiviral response" are cells which respond to low levels (e.g., 10 units per ml) of exogenous interferon by significantly reducing (at least 10-fold, more advantageously at least 100-fold, more advantageously at least 1000-fold, and most advantageously at least 10,000-fold) the replication of an interferon-sensitive virus as compared to in the absence of interferon. The degree of virus replication is determined by measuring the amount of virus (e.g., infectious virus, viral antigen, viral nucleic acid). CCD922 normal fibroblasts are cells competent in an interferon-mediated antiviral response.

[0062] Cells deficient in an interferon-mediated antiviral response. As used herein, the term "cells deficient in an interferon-mediated antiviral response" are cells which fail to meet the criteria listed above for a cell competent in an interferon-mediated antiviral-response, that is, they fail to respond to low levels (e.g., 10 units per ml) of exogenous interferon by significantly reducing the replication of an interferon-sensitive virus as compared to in the absence of interferon. KB oral carcinoma cells are cells deficient in an interferon-mediated antiviral response.

[0063] Clonal. Use of the term "clonal" virus is defined hereafter as virus derived from a single infectious virus particle and for which individual molecular clones have significant nucleic acid sequence homology. For example, the sequence homology is such that at least eight individual molecular clones from the population of virions have sequence homology greater than 95%, more advantageously greater than 97%, more advantageously greater than 99%, and most advantageously 100% over 300 contiguous nucleotides.

[0064] Cytocidal. As used herein, the term "cytotoxic" virus refers to a virus that infects cells resulting in their death.

[0065] Desensitizing Dose. As used herein, the phrase, "desensitizing dose" refers to the amount of virus required to lessen the side effects of subsequent doses of the virus.

[0066] Differential Cytotoxicity Assay. As used herein, the phrase "differential cytotoxicity assay" for screening tumor cells or tissue using a virus refers to the (a) virus infection of the tumor cells and one or more control cells or tissue; (b) a determination of cell survivability or death for each sample (for example, by the use of a dye indicator of cell viability as in detailed in Example 1) after one or more days of infection; and (c) based on the results, an estimation of the sensitivity (for example, by IC50 determination as detailed in Example 1) of the sample to the virus compared to

the control(s).

[0067] Infecting a Neoplasm. As used herein, the term "infecting a neoplasm" refers to the entry of viral nucleic acid into the neoplastic cells or tissues.

[0068] Interferon-sensitive. As used herein, the phrase "interferon-sensitive" virus (e.g., NDV) means a virus that replicates significantly less (at least 10-fold less, advantageously at least 100-fold less, more advantageously at least 1000-fold less, and most advantageously at least 10,000-fold less), in the presence of interferon compared to in the absence of interferon. This is determined by measuring the amount of virus (e.g., infectious virus, viral antigen, viral nucleic acid) obtained from cells competent in an interferon-mediated antiviral response in the presence or absence of low levels of exogenous interferon (e.g., 10 units per ml).

[0069] Neoplasm and Neoplastic Disease. As used herein, "neoplasm" means new growth of tissue, including tumors, benign growths (e.g., condylomas, papillomas) and malignant growths (e.g., cancer). As used herein, "neoplastic disease" refers to disease manifested by the presence of a neoplasm.

[0070] Replication Competent. As used herein, the term "replication-competent" virus refers to a virus that produces infectious progeny in neoplastic cells.

[0071] Substantially Free of Contaminating Egg Proteins. The term "substantially free of contaminating egg proteins" refers to a level of virus purity in which ovalbumin is not detectable in a Western blot as performed by one skilled in the art by (1) using 1.7×10^9 PFU of virus per well (3.3 cm in width) run on an SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) gel (1 mm thick); (2) transferring the viral proteins from the gel to a nitrocellulose membrane; and (3) immunostaining for ovalbumin with the use of a rabbit anti-ovalbumin [Rabbit IgG fraction at a 1:200 dilution of a 4 mg/ml antibody concentration (from Cappel. Inc.) or equivalent polyclonal antibody].

[0072] Therapeutically effective amount. As used herein, the term "therapeutically effective amount" when referring to the treatment of neoplastic disease refers to a quantity of virus which produces the desired effect, e.g., cessation of neoplastic growth, tumor regression, improved clinical conditions, or increased survival.

Compounds of the Invention

[0073] A diverse group of viruses are used to selectively kill neoplastic cells. Natural or engineered viruses can function as an antineoplastic agent. These viruses i) infect neoplastic cells resulting in their death; ii) are replication-competent in the neoplastic cells; and iii) are limited in killing of normal cells by the antiviral effects of interferon.

[0074] In an advantageous embodiment of the invention, the viruses possessing the above three characteristics [(i) they infect neoplastic cells resulting in their death; (ii) they are replication-competent in the neoplastic cells; and (iii) they are limited in killing of normal cells by the antiviral effects of interferon] also induce interferon.

[0075] In another advantageous embodiment of the invention, the viruses possessing the above three characteristics also cause regression of human neoplasms; and/or are not neutralized in the target human population because of the presence of pre-existing immunity.

[0076] In another advantageous embodiment, the viruses possessing the above three characteristics are cytotoxic to tumor cells.

[0077] A Paramyxovirus (as used herein "Paramyxovirus" refers to a member of the Paramyxoviridae) can be used according to the present invention to treat a neoplasm including a large tumor or a host having a high tumor burden. The Paramyxoviridae family comprises three genera: (1) paramyxoviruses; (2) measles-like viruses (morbilli viruses); and (3) respiratory syncytial viruses (pneumoviruses). These viruses contain an RNA genome. Use of Paramyxoviridae viruses which are cytotoxic, especially paramyxoviruses, e.g., Newcastle disease virus ("NDV") and other avian paramyxoviruses such as avian paramyxovirus type 2, is an advantageous method of practicing the invention. Attenuated strains of these viruses are especially useful for treatment of neoplasms in accordance with the present invention.

[0078] NDV is an especially advantageous virus according to the present invention. NDV is categorized into three distinct classes according to its effects on chickens and chicken embryos. "Low virulence" strains are referred to as lentogenic and take 90 to 150 hours to kill chicken embryos at the minimum lethal dose (MLD); "moderate virulence" strains are referred to as mesogenic and take 60 to 90 hours to kill chicken embryos at the MLD; "high virulence" strains are referred to as velogenic and take 40 to 60 hours to kill chicken embryos at the MLD. See, e.g., Hanson and Brandly, 1955 (Science, 122:156-157), and Dardiri et al., 1961 (Am. J. Vet. Res., 918-920). All three classes are useful, advantageously, mesogenic strains of NDV such as strain MK107, strain NJ Roakin, and strain Connecticut-70726. (see Examples 21-23). See, e.g., Schloer and Hanson, 1968 (J. Virol., 2:40-47) for a listing of other mesogenic strains.

[0079] It is desirable to obtain a clonal virus to ensure or increase the genetic homogeneity of a particular virus strain and to remove defective interfering particles. Removal of defective interfering particles by cloning allows for increased purity in the final product as assessed by the number of total virus particles per infectious particle (e.g., the number of particles per PFU).

[0080] Clonal virus can be produced according to any method available to the skilled worker. For example, plaque purification is routinely utilized to obtain clonal virus. See, e.g., Maassab et al., In: Plotkin and Mortimer, eds. Vaccines,

Philadelphia: W.B. Saunders Co., 1994, pages 78-801. Triple plaque purification is especially desirable, where a plaque is selected at each round of purification having the desired characteristics, such as a preferred size, shape, appearance, or representative of the parental strain. Another means of generating clonal virus is by recombinant DNA techniques applicable by one skilled in the art. Another means of obtaining a clonal virus applies the technique of limiting dilution (e.g., by adding dilutions of the virus sample to give an average of one or less infectious virus particles per well containing a monolayer of a susceptible cell).

[0081] In an advantageous embodiment of the invention, purified virus is used to treat neoplastic diseases. An advantageous method for purification of egg derived viruses are as follows (virus is not pelleted at any step in these methods):

10 Purification Method A

[0082]

- a) generating a clonal virus (e.g., plaque purification)
- 15 b) inoculating eggs with the clonal virus
- c) incubating the eggs
- d) chilling the eggs
- e) harvesting the allantoic fluid from the eggs
- f) removing cell debris from the allantoic fluid
- 20 g) ultracentrifugation of the allantoic fluid without pelleting (e.g., using a discontinuous sucrose gradient)

[0083] In another embodiment of the invention, additional steps, added after the removal of the cell debris (from the allantoic fluid) and before ultracentrifugation, consist of:

- 25 • freezing then thawing the allantoic fluid,
- removing contaminating material from the virus suspension (e.g., by means of centrifugation)

[0084] In another embodiment of the invention, ultracentrifugation is accomplished by means of a continuous flow ultracentrifuge.

30 **[0085]** One embodiment of the invention relates to a method of purifying a replication-competent RNA virus comprising the steps of

- a) generating a clonal virus, and
- 35 b) purifying said clonal virus by ultracentrifugation without pelleting.

[0086] Another embodiment of the invention involves a method of purifying a paramyxovirus (e.g., NDV) comprising purifying the virus by ultracentrifugation without pelleting.

[0087] Optionally, the purifying step additionally comprises prior to the ultracentrifugation:

- 40 a) plaque purifying to generate a clonal virus,
- b) inoculating eggs with the clonal virus,
- c) incubating the eggs,
- d) chilling the eggs,
- e) harvesting allantoic fluid from the eggs and,
- 45 f) removing cell debris from the allantoic fluid.

[0088] Another embodiment of the invention involves a method of purifying a replication-competent clonal virus from eggs or cell culture comprising the step of ultracentrifugation without a step in which the virus is pelleted.

50 **[0089]** Another embodiment of the invention involves a method of the purifying a paramyxovirus (e.g., NDV) comprising purifying the virus by sequential tangential flow filtration (TFF).

Optionally, the virus can be additionally purified by gel permeation chromatography, where each of these steps occurs in the presence of a stabilizing buffer (Example 15):

- 55 a) plaque purifying to generate a clonal virus,
- b) inoculating eggs with the clonal virus,
- c) incubating the eggs,
- d) chilling the eggs,
- e) harvesting allantoic fluid from the eggs and dilution of allantoic fluid with buffer,

- f) removing cell debris from the allantoic fluid by TFF,
- g) purification of the virus by TFF, and
- h) purification of the virus by gel permeation chromatography.

5 [0090] Optionally, the virus obtained from the gel permeation step can be concentrated using TFF.

[0091] Another embodiment of the invention involves a method of purifying a replication-competent clonal virus from eggs or cell culture comprising the step purifying the virus by sequential tangential flow filtration (TFF), optionally followed by gel permeation chromatography, optionally followed by TFF to concentrate the virus.

10 Clonal virus

[0092] Use of these methods permits purification of a clonal virus [including Paramyxovirus (e.g., NDV)] to at least 2×10^9 PFU/mg protein, advantageously to at least 3×10^9 PFU/mg protein, more advantageously to at least 5×10^9 PFU/mg protein, more advantageously to at least 1.0×10^{10} PFU/mg protein, more advantageously to at least 2.0×10^{10} PFU/mg protein, more advantageously to at least 3×10^{10} PFU/mg protein, more advantageously to at least 4×10^{10} PFU/mg protein, more advantageously to at least 5×10^{10} PFU/mg protein, and most advantageously at least 6×10^{10} PFU/mg.

[0093] Use of these methods permits purification of a clonal virus [including Paramyxovirus (e.g., NDV)] to level in which the number of virus particles per PFU is less than 10, more advantageously less than 5, more advantageously less than 3, more advantageously less than 2, and most advantageously less than 1.2. (Lower numbers of virus particles per PFU indicate a higher degree of purity.)

RNA viruses

25 [0094] In another embodiment, these methods permit purification (to the levels cited above for clonal viruses) of an RNA virus [including (a) a cytotoxic RNA virus; (b) a single-stranded RNA non-segmented, nonenveloped virus; (c) a single-stranded RNA segmented, enveloped virus; (d) a double-stranded RNA segmented, nonenveloped virus; (e) and a single-stranded RNA non-segmented, enveloped virus (e.g., Paramyxovirus (e.g., NDV) and e.g., Retroviruses].

30 DNA viruses

[0095] In another embodiment, these methods permit purification (to the levels cited above for clonal viruses) of an interferon-sensitive cytotoxic virus selected from the group consisting of (a) enveloped, double-stranded DNA viruses (including poxviruses); (b) nonenveloped, single-stranded DNA viruses; and (c) nonenveloped, double-stranded DNA viruses.

Egg derived viruses

40 [0096] In another embodiment, these methods permit purification of egg derived viruses to a level substantially free of contaminating egg proteins. It is preferred to limit the amount of egg proteins in virus preparations for human therapeutic use since major egg proteins like ovalbumin are allergens.

[0097] Viruses useful in the treatment of neoplastic diseases including cancer are shown in Table 1. These viruses are optionally screened for naturally occurring variations (certain strains or isolates) that result in altered IFN production relative to the parental strain.

Table 1

Naturally Occurring Viruses for Use in Cancer Therapy		
Virus Class	Virus Family	Virus Example
RNA, negative stranded	Paramyxoviridae	Newcastle Disease Virus
		Avian Paramyxovirus Type 2
		Mumps
		Human Parainfluenza

(continued)

Naturally Occurring Viruses for Use in Cancer Therapy		
Virus Class	Virus Family	Virus Example
	Rhabdoviridae	Vesicular Stomatitis Virus
RNA. positive stranded	Togaviridae	Sindbis Virus
	Flaviviridae	Yellow Fever Virus (attenuated)
	Picomaviridae	Rhinovirus
		Bovine Enterovirus
		Echovirus
	Coronaviridae	Avian Infectious Bronchitis Virus
		Human Coronaries

[0098] In another embodiment of this invention, candidate viruses, whether naturally occurring or engineered, are tested for the ability to provide therapeutic utility in the treatment of neoplasms. In one embodiment, the amount of candidate virus required to kill 50% of cells deficient in an interferon-mediated antiviral response, e.g., KB head and neck carcinoma cells, is compared to the amount of virus required to kill 50% of a similar number of cells competent in an interferon-mediated antiviral response, for example normal skin fibroblasts. The amount of killing is quantified by any number of means including trypan blue exclusion or MTT assay (see Example 1). A significant reduction (e.g., at least 5-fold) in the amount of virus required to kill cells deficient in an interferon-mediated antiviral response relative to the amount needed to kill cells competent in an interferon-mediated antiviral response indicates that the virus being tested exhibits activity required for therapeutic utility in the treatment of neoplasms. Other NDV viruses and Sindbis virus are such natural occurring viruses that display tumor-selective killing (see Examples 21-23, and 25).

[0099] An understanding of the factors involved in the establishment of an antiviral state allows for the creation of a screening assay for tumors that are likely to respond to viral therapy. In principle, patient derived tumor tissue obtained from biopsy is screened for the expression of p68 kinase, p58, or other factors involved in the regulation of an antiviral state or cellular differentiation. Other factors include, but are not limited to, interferon response factor-1 (IRF-1), interferon stimulatory gene factor-3 (ISGF-3), c-Myc, c-Myb, and IFN receptors. In the case of c-Myc, c-Myb or p58, high level expression indicates that the tumor tissue or cells are treatment candidates for virus therapy. In the case of p68, IRF-1, ISGF-3, and IFN receptors, low level expression indicates that the tumor tissue or cells are treatment candidates for virus therapy.

[0100] In another embodiment of this invention, primary tumor tissue or cells obtained from patient biopsies are expanded in culture and tested for sensitivity to killing by a suitable viral therapy. In one embodiment, the amount of virus required to kill 50% of the tumor tissue culture is compared to the amount required to kill 50% of a culture of normal cells as described above for the screening of candidate viruses. An increase of ten-fold or greater in the sensitivity of the tumor cells relative to normal cells to killing by the viral agent indicates that the tumor cells are specifically sensitive to the cytotoxic effects of the viral treatment. In a further embodiment of the invention, the ability of the targeted tumor cells to respond to endogenously or exogenously supplied IFN is determined by conducting the above screen in the presence of IFN (alpha or beta form, using e.g., 10 units per ml, see Example 27).

[0101] An understanding of the cellular receptors required for virus attachment or entry allows additional screening for tumors that have high receptor expression and hence enhanced sensitivity to the interferon-sensitive virus. This is an additional level screening for patients that are likely to respond to virus therapy. Advantageously for therapy with an interferon-sensitive virus, the patient's tumor is both resistant to interferon and has high expression of the cellular receptor for the virus. In principle, patient derived serum, tumor cells, tissues, or tissue sections are screened by immunoassay or immunostain for the amount of virus receptor present in the serum or on the tumor cells or tumor tissue. For example, Sindbis virus utilizes the high affinity laminin receptor to infect mammalian cells (Wang et al., 1992, J Virol., 66, 4992-5001). This same receptor is known to be expressed in higher amounts in many diverse types of metastatic cancer. The PANC-

1 renal cancer cell line, and the colon adenocarcinoma cell line SW620 are known to express a high level of high affinity laminin receptor mRNA (Campo et al, 1992, Am J Pathol 141:107301983; Yow et al., (1988) Proc. Natl Acad Sci, 85, 6394-6398) and are highly sensitive to Sindbis virus (Example 25). In contrast, the rectum adenocarcinoma cell line SW 1423 is known to express very low levels of high affinity laminin receptor mRNA (Yow et al., (1988) Proc. Natl Acad Sci,

5 85, 6394-6398), and is more than 4 orders of magnitude more resistant to killing by PPSINDBIS-Ar339 than SW620 cells. [0102] Existing strains of NDV, or other viruses including RNA and DNA viruses, are screened or engineered for altered IFN responses (e.g., advantageously increased IFN responses) in normal cells. In addition to the ability to elicit a strong IFN response, other viral characteristics are screened for or engineered into the virus. Viruses with altered receptor specificity (e.g., Sindbis virus PPSINDBIS-Ar339, see Example 25), or low neurovirulence are included in the

10 subject invention (e.g., NDV virus PPNJROAKIN, see Example 24). Advantageously, viruses of the invention have the capacity to spread through direct cell to cell contact. [0103] The invention described herein includes a broad group of viruses (see Table 1) that are useful for treatment of neoplasms in a manner analogous to the indication for NDV. In addition, viruses that naturally would not be candidates for use, due to the presence of a mechanism(s) to inactivate the IFN response in normal cells, are optionally engineered

15 to circumvent the above restrictions. If left unmodified, viruses with mechanisms to inactivate the interferon response would be more toxic to normal cells than viruses with such mechanism removed. The subject invention provides (1) the development of a vector that can be easily manipulated; and (2) the creation of a set of therapeutic viruses. Manipulations include the addition of an IFN gene to permit the viral expression of a transgene expressing IFN, or other activators of the IFN response pathway. Additional permutations include the engineered expression of pro-drug activating enzymes

20 such as the Herpesvirus thymidine kinase or cytosine deaminase (Blaese RM et al., 1994, Eur. J. Cancer 30A: 1190-1193) and the expression of suitable marker antigen to allow targeting of tumor cells by the immune system. An additional permutation include the engineered expression of receptor ligands to target cells with those receptors [e.g., expression of receptors to other viruses to target cells infected with those viruses (see Mebastsion et al., 1997, Cell 90:841-847; and Schnell MJ et al., 1997, Cell 90:849-857].

25 [0104] Several Newcastle Disease virus strains demonstrate selective killing of tumor cells. In a differential cytotoxicity assay using a second strain of mesogenic Newcastle Disease virus, tumor cells were found to be 3 orders of magnitude more sensitive than normal cells to killing by the virus (Example 21). Additionally, when a third mesogenic Newcastle Disease virus strain was used in a differential cytotoxicity assay, tumor cells were found to be 80 to 5000-fold more sensitive than normal cells to killing by the virus (Example 22). Both of these mesogenic Newcastle Disease virus strains

30 also caused tumor growth regression following intratumoral administration to athymic mice bearing human tumor xenografts (Example 23).

[0105] In separate experiments, the safety of three distinct Newcastle Disease virus strains were studied following intracerebral inoculation in athymic and immune-competent mice. The results of this study showed that all three virus strains were well tolerated in mice with an intact immune system. Intracerebral inoculation into the brains of athymic

35 mice revealed that one of the viruses was tolerated significantly better than the other two (Example 24). These results demonstrate that within a single virus family important differences in viral properties can occur and be can be exploited therapeutically for greater efficacy or increased safety.

[0106] Another means by which increased efficacy and lower toxicity following treatment with oncolytic viruses can be achieved is through the use of interferon-sensitive viruses that require specific cell surface receptors that are preferentially expressed on tumor cells. Sindbis virus provides an example of this type of restriction. Sindbis virus infects

40 mammalian cells using the high affinity laminin receptor (Wang et al., (1992) J. Virol. 66, 4992-5001). When normal and tumor cells were infected with Sindbis virus in a differential cytotoxicity assay, cells which both were tumorigenic and expressed the high affinity laminin receptor were found to be more sensitive to killing by this virus than other cells (Example 25). Normal keratinocytes express the high affinity laminin receptor (Hand et al., (1985) Cancer Res., 45, 2713-2719), but were resistant to killing by Sindbis in this assay.

[0107] Vesicular Stomatitis Virus (VSV) provides evidence of tumor-selective killing by oncolytic viruses, i.e., an inherent deficiency in interferon responsiveness in tumor cells renders these cells sensitive to killing by interferon-sensitive replication-competent viruses when VSV is used to infect non-tumorigenic human WISH cells and tumorigenic HT1080 or KB cells in the presence of exogenous interferon.

50 [0108] Below is a list of viruses that when modified to remove naturally-occurring anti-interferon activities, are useful for viral cancer therapy (see Table 2). Modified viruses (advantageously, but not necessarily, attenuated in addition to the anti-interferon modification, see Table 3) that have had endogenous anti-interferon activities destroyed or reduced, are useful for cancer therapy. This list includes, but is not be limited to, the viruses described below. Because of the similarity between viruses of a common class, the identified mechanisms for each of the specific viruses listed below,

55 are also present in other members of that class of virus as identical or functionally analogous mechanisms. The broader group of viruses is added in parenthesis. Viruses, such as those below, that have a functional loss of anti-interferon activity, through any means, including natural occurring mutations, as well as engineered deletions or point mutations, are useful in the methods of the subject invention.

[0109] Viruses that exercise more than one mechanism are optionally modified to contain mutations in one, some, or all of the activities. Mutations for some of the described activities are available in the general scientific community.

[0110] Isolates of naturally occurring or engineered virus that are slower growing, compared to the growth rate of wild-type virus, are particularly advantageous because a slower virus growth rate will allow a cell or population of cells competent in an interferon response to establish an efficient antiviral state before viral replication can kill the cell or cell population.

[0111] The disabling of viral anti-interferon activities as a specific alteration of viral character that results in the augmentation of the interferon response in an infected cell, but still allows viral replication in neoplastic cells is included in the subject invention.

[0112] Table 2 shows existing viruses engineered to remove anti-interferon activity.

[0113] Table 3 lists viruses engineered to be attenuated in virulence.

Table 2

Extant Viruses Engineered to Remove Anti-IFN Activity				
Virus Class	Virus Family	Virus	Anti-IFN Activity	Reference
RNA	Reoviridae	reovirus	$\sigma 3$	Imani F and Jacobs B (1988) Proc Natl Acad Sci USA 85:7887-7891.
DNA	Poxviridae	vaccinia	K3L	Beattie E et al. (1991) Virology 183:419
			E3L	Beattie E et al. (1996) Virus Genes 12:89-94.
			818R	Symons JA et al. (1995) Cell 81:551-560.
	Adenoviridae	Various subtypes	VA, transcripts	Mathews MB and Shenk T (1991) J Virol 64: 5657-5662.
	Alphaherpesvirinae	HSV-1	gamma 34.5 gene product	Chou J et al (1996) Proc Natl Acad Sci USA 92: 10516-10520.

Table 3

Known Attenuating Mutations in Selected Viruses				
Virus Class	Virus Family	Virus	Attenuation	Reference
RNA	Reoviridae	reovirus	$\sigma 1$	Spriggs DR and Fields BN (1982) Nature 297:68-70.
		rotavirus	bovine strains (WC3)	Clark HF (1988) J Infect Dis 158:570-587.
DNA	Poxviridae	vaccinia	vaccinia growth factor	Buller RML et al (1988) Virology 164:182.

(continued)

Known Attenuating Mutations in Selected Viruses				
Virus Class	Virus Family	Virus	Attenuation	Reference
			thymidine kinase	Buller RML et al (1985) Nature 317:813-815.
			thymidylate kinase	Hughes SJ et al (1991) J Biol Chem 266: 20103-20109
			DNA ligase	Kerr SM et al (1991) EMBO J 10:4343-4350.
			ribonucleotide reductase	Child SJ et al (1990) Virology 174:625-629.
			dUTPase	Perkus ME et al (1991) Virology 180:406-410.
	Adenoviridae	various subtypes	Ad-4, Ad-7, Ad-21	Takafugi ET et al (1979) J Infect Dis 140:48-53.
	Alphaherpesvirinae	HSV.1	thymidine kinase	Field HJ and Wildy P (1978) J Hyg 81:267-277.
			ribonucleotide reductase	Goldstein DJ and Weller SK (1988) Virology 166:41-51.
			gamma 34.5 gene product	Chou J et al (1995) Proc Natl Acad Sci USA 92: 10516-10520.
			b'a'c' inverted repeats	Meignier B et al (1988) J Infect Dis 162:313-322.

Treatment of Neoplasms

[0114] The present invention relates to viral therapy of neoplasms, especially in animals having cancer. In an advantageous embodiment, the invention relates to the treatment of tumors which are 1 centimeter (cm) or more in size as measured in the greatest dimension. As used herein, "a 1 cm tumor" indicates that at least one dimension of the tumor is 1 cm in length. Such tumors are more sensitive than expected to viral therapy, often at least as sensitive to virus, if not more sensitive, than tumors which are smaller in size. In a more advantageous aspect of the invention, tumors greater than 1 cm. are treated, e.g., tumors which are 2 cm or greater, from about 2 cm to about 5 cm, and greater than 5 cm. -

[0115] The present invention can also be employed to treat hosts having a high tumor burden. As used herein, the phrase "tumor burden" refers to the total amount of tumor within the body expressed as a percentage as body weight. Viral therapy of hosts having a tumor burden, e.g., from about 1% to about 2% of total body weight is surprisingly effective, e.g., producing tumor regression and a reduction in the overall tumor load. This is especially unexpected since a tumor burden of approximately 2% of the total body weight (e.g., a 1 kg tumor in a 60 kg human) is approximately the maximum cancer mass compatible with life. See, e.g., Cotran et al., In Robbins Pathological Basis of Diseases, 4th Edition, WB Saunders, 1989, page 252. In the Examples, volumes up to 397 mm³ for a melanoma cancer (e.g., A375) in a mouse host showed complete regression in response to treatment with a Newcastle disease virus (e.g., a triple-plaque purified virus). Assuming that for tissue 1000 mm³ equals 1 gram, a tumor having a volume of 397 mm³ comprises approximately 2% of the total body weight for a 20 gram mouse.

[0116] As shown in Examples 4 to 9 below, tumor regression was achieved with tumors at least 1 cm in size, while untreated, control animals began dying from tumor burden within several weeks. Thus, such diseased animals were successfully treated despite being within two weeks of death. Thus, in accordance with the present invention, an animal which is near terminal from its tumor burden can be treated effectively with viral therapy. Consequently, the present

invention can be used to treat patients who have not responded to conventional therapy, e.g., chemotherapy such as methotrexate, 5-fluorouracil, and radiation therapy.

[0117] The efficacy of NDV for the treatment of cancer following administration through the intraperitoneal route has also been examined. Using an ascites prevention model of ovarian cancer, intraperitoneal injection of NDV in mice harboring ES-2 human ovarian tumors resulted in increased survival compared to mice treated with saline (Example 16). When ES-2 cells were used in an ovarian cancer tumor model with treatment initiated once ascites formed, ascites fluid production was markedly decreased in virus-treated animals compared to saline controls (Example 17).

[0118] In another embodiment of the invention, the administration of virus results in 1) the relief of tumor related symptoms, such as but not limited to decreased rate of ascites fluid production, relief of pain, and relief of obstructive disease, and 2) the prolongation of life.

[0119] Twenty-three patients have received the plaque purified NDV isolate by the intravenous route (Example 20). Treatment responses include the regression of a palpable tumor, the stabilization of disease in 47% of patients and a reduction in pain medication.

Administration and Formulation

[0120] In one embodiment of the invention, tumor cells or tissue are screened *in vitro* to determine those patients with tumors sensitive to the virus. Tumor cells removed from the patient (by methods such as fine needle aspiration for solid tumors or by paracentesis for ovarian ascites tumors) are grown *in vitro* and incubated with virus. In this embodiment of the invention, patients are selected for therapy if the virus has a high activity against their tumor cells.

[0121] In an advantageous embodiment of the invention, the amount of virus administered results in regression of the tumor or tumors. As used herein, the term "regression" means that the tumor shrinks. e.g., in size, mass, or volume. Shrinkage in tumor size is demonstrated by various methods, including physical examination, chest film or other x-ray, sonography, CT scan, MRI, or a radionucleotide scanning procedure.

[0122] Various types of neoplasms including cancers are treatable in accordance with the invention. The viruses of the present invention are useful to treat a variety of cancers, including but not limited to lung carcinoma, breast carcinoma, prostate carcinoma, colon adenocarcinoma, cervical carcinoma, endometrial carcinoma, ovarian carcinoma, bladder carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, melanoma, synovial sarcoma, neuroblastoma, lymphoma, leukemia, brain cancer including glioblastoma, neuroendocrine carcinoma, renal carcinoma, head and neck carcinoma, stomach carcinoma, esophageal carcinoma, vulvar carcinoma, sarcoma, skin cancer, thyroid pancreatic cancer, and mesothelioma. The viruses of the present invention are also useful to treat a variety of benign tumors, including but not limited to condylomas; papillomas, meningiomas, and adenomas.

[0123] A therapeutically effective amount of virus is administered to a host having a neoplasm. It is understood by those skilled in the art that the dose of virus administered will vary depending on the virus selected, type of neoplasm, the extent of neoplastic cell growth or metastasis, the biological site or body compartment of the neoplasm(s), the strain of virus, the route of administration, the schedule of administration, the mode of administration, and the identity of any other drugs or treatment being administered to the mammal, such as radiation, chemotherapy, or surgical treatment. These parameters are defined through maximum tolerated dose determination in animal models and scaling to human dosage as a function of relative body surface area or body mass. It is also understood that under certain circumstances, more than one dose of the virus is given. The optimal interval between such multiple doses of the virus can be determined empirically and is within the skill of the art. NDV is generally administered from about 3×10^6 to about 5×10^{12} PFU of virus. For local administration (e.g., directly into a tumor), total amounts of from about 3×10^6 to about 5×10^{10} PFU of virus are typically used. For systemic administration, amounts of from about 1×10^8 to about 4×10^{11} PFU of virus per square meter of body surface area are used. For intravenous administration, dosing schedules of once per week, two times per week and three times per week are used. A virus in accordance with the present invention, optionally with a chemotherapeutic agent, can be administered by various routes, e.g., enteral, parenteral, oral, nasal, rectal, intrathecal, intravenous (e.g., using a catheter), subcutaneous, intratumor (e.g., directly into its tissue or into vessels which perfuse it), peritumoral, local, sublingual, buccal, topical, intramuscular, by inhalation, percutaneous, vaginal, intra-arterial, intracranial, intradermal, epidural, systemically, topical, intraperitoneal, intrapleural, etc. For lung tumors, a bronchial route (e.g., bronchial administration) can be used. Endoscopic injections of gastrointestinal tumors, as well as suppository treatments of rectal tumors are also used where appropriate.

[0124] Murine toxicity studies with NDV have indicated that the acute toxicity following intravenous virus administration is likely to be caused by cytokine mediated reactions. Cytokine responses to repeated stimuli are known to be desensitized, or down-regulated, following the initial induction event (Takahashi et al., (1991) Cancer Res. 51, 2366-2372). Mice intravenously injected with a desensitizing dose of virus were able to tolerate approximately 10-fold more virus on a second dose than mice receiving vehicle alone for the first injection (Example 18).

[0125] The rate of virus administration by the intravenous route can significantly affect toxicity. Two groups of athymic mice were intravenously treated with identical doses of NDV which was administered either slowly (0.2 ml over 4 minutes)

or rapidly (0.2 ml over 30 seconds). Comparison of the maximal weight loss in each group revealed 50% less weight loss in the group receiving slow injection versus a rapid injection (Example 19).

[0126] In one cohort of a clinical trial, patients received three injections of the plaque purified NDV isolate over the course of one week (Example 20). Under these conditions, a desensitizing effect of the initial dose lessened the toxicity associated with the second and third doses. These data parallel those obtained with the animal studies shown in Example 18. One concern related to the use of oncolytic viruses in the treatment of cancer is the potential inhibitory effect the humoral immune response can exert on the therapy. In the clinical study, patients displaying stable disease after 1 month are eligible for a second course of treatment which then is administered in the presence of neutralizing antibodies to NDV. Nevertheless, infectious virus could be found in patient urine seven days after dosing for the second course, providing evidence that administration of high doses of virus can overcome the effect of neutralizing antibodies and establish an infection within the patient.

[0127] In an advantageous embodiment of the invention, a desensitizing dose is given before higher subsequent doses. For desensitization, virus doses of 1×10^8 to 2.4×10^{10} PFU/m² are used. After desensitization, additional virus doses of 3×10^8 to 4×10^{12} PFU/m² are used. The time frame between doses, including the time frame between desensitizing dose and the next dose, is 1 to 14 days, advantageously 1 to 7 days. The desensitizing dose can be administered by various routes, e.g., intravenous, enteral, parenteral, oral, nasal, rectal, intrathecal, intravenous, subcutaneous, intratumor, peritumoral, local, sublingual, buccal, topical, intramuscular, by inhalation, percutaneous, vaginal, intra-arterial, intracranial, intradermal, epidural, systemically, topical, intraperitoneal, intrapleural, endoscopic, intrabronchial, etc. The subsequent doses can be administered by the same route as the desensitizing dose or by another route, e.g., intravenous, enteral, parenteral, oral, nasal, rectal, intrathecal, intravenous, subcutaneous, intratumor, peritumoral, local, sublingual, buccal, topical, intramuscular, by inhalation, percutaneous, vaginal, intra-arterial, intracranial, intradermal, epidural, systemically, topical, intraperitoneal, intrapleural, endoscopic, intrabronchial, etc.

[0128] Optionally, more than one route of administration can be used in either a sequential or concurrent mode. Routes for either concurrent or sequential administration include but are not limited to intravenous, enteral, parenteral, oral, nasal, rectal, intrathecal, intravenous, subcutaneous, intratumor, peritumoral, local, sublingual, buccal, topical, intramuscular, by inhalation, percutaneous, vaginal, intra-arterial, intracranial, intradermal, epidural, systemically, topical, intraperitoneal, intrapleural, endoscopic, intrabronchial, etc. An example would be the administration of a intravenous desensitizing dose followed by an intraperitoneal dose.

[0129] In another advantageous embodiment of the invention, the virus is administered by slow infusion including using an intravenous pump or slow injection over the course of 4 minutes to 24 hours.

[0130] A virus, and optionally one or more chemotherapeutic agents, is administered by a single injection, by multiple injections, or continuously. The virus is administered before, at the same time, or after the administration of chemotherapeutic agents (such as but not limited to: busulfan, cyclophosphamide, methotrexate, cytarabine, bleomycin, cisplatin, doxorubicin, melphalan, mercaptopurine, vinblastine, 5-fluorouracil, taxol, and retinoic acid). Viral therapy in accordance with the present invention is optionally combined with other treatments, including, surgery, radiation, chemotherapy (see, e.g., Current Medical Diagnosis and Treatment, Ed. Tierney et al., Appleton & Lange, 1997, especially pages 78-94), and biological therapy. The virus is administered before, at the same time, or after the administration of biological agents such as (1) other oncolytic agents [such as but not limited to: adenoviruses with one of its genes under transcriptional control of a prostate cell specific response element (see Rodrigues, R. et al, 1997, Cancer Res, 57:2559-2563; adenoviruses which do not encode a E1b polypeptide capable of binding p53 (see Bischoff, J.R., et al, 1996, Science 274:373-376); a herpes simplex virus that is incapable of expressing a functional gamma 34.5 gene product (see Mineta, T. et al, 1995, Nature Medicine, 1:938-943)]; (2) cytokines (such as but not limited to: colony stimulating factors such as GM-CSF; tumor necrosis factor, and interleukins such as IL-1, IL-2, IL-6 and IL-10); (3) viral vectors [such as but not limited to adenovirus encoding p53 (see Zhang, WW et al, 1994, Cancer Gene Therapy, 1:5-13)]; and (4) cancer vaccines. In one embodiment of the invention, therapy consists of the serial treatment with antigenically distinct viruses which are cytotoxic and tumor selective via the IFN mechanism. This embodiment allows viral therapy over an extended period without immunological interference.

[0131] Another embodiment involves the treatment of patients with IFN (e.g. α IFN, β IFN or γ IFN) prior to, concurrent with, or following administration of NDV (or other virus). The IFN is selected from the group class I (alpha, beta and omega) and class II (gamma), and recombinant version and analogs thereof as discussed in, for example, Sreevalsoun, T., 1995 (In: Biologic Therapy of Cancer, second edition, edited by V.T. DeVita, Jr., S. Hellman, and S.A. Rosenberg, J.B. Lippincott Company, Philadelphia, pp347-364). Normal cells respond to the IFN pre-treatment with an augmented IFN response to viral infection affording even greater safety to these cells. Tumor cells deficient in the IFN signaling pathway remain sensitive to killing by the virus. This allows even higher doses of viral therapy to be used. The IFN is administered in accordance with standard clinical guidelines for doses and regimens known to be effective for treating viral infections. In another embodiment of the invention, other drugs, known to affect the IFN response pathway are also optionally used to increase the sensitivity of tumor cells, or increase the resistance of normal cells to the cytotoxic effects of viral infection. This class of drugs includes, but is not limited to tyrosine kinase inhibitors, cimetidine, and mitochondrial

inhibitors. Hypoxia and hyperthermia are also known to modulate interferon responsiveness.

[0132] In another embodiment of the invention, immunosuppressants such as cyclosporin A, azathiaprime, and leflunomide, various corticosteroid preparations, and anti-CD-40 ligand antibodies (Foy, T.M., et al., 1993, J. Exp. Med. 178: 1567-1575) are administered with the virus. Alternatively, an immunostimulatory compound, e.g., lipopeptides, can be administered with the virus.

[0133] An independent mechanism by which the amount of interferon produced in response to viral infection is increased through the use of nucleosides (Machida, H., 1979. Microbiol. Immunol. 23:643-650), nucleoside precursors, or drugs that increase the cellular concentration of one or more nucleosides, are optionally used as an adjunct to viral therapy.

[0134] Certain purine nucleoside analogs, e.g., 2-chlorodeoxyadenosine and 2'-deoxycoformycin, reduce interferon production in vivo. Such compounds are used to further effect differences in interferon sensitivities of tumor cells versus normal cells and are optionally used as an adjunct to viral therapy.

[0135] In one aspect, an effective amount of virus can be subdivided into smaller dose units and injected at the same time into different locations of the same tumor. For continuous administration, the desired agent(s) is administered via an implanted minipump or it is impregnated into a desired polymer and then transplanted into a desired location (e.g., directly into the tumor) for slow or delayed release.

[0136] A virus of the present invention is formulated as a pharmaceutical preparation by bringing it into a suitable dose form, together with at least one excipient or auxiliary, and, if desired, with one or more further active compounds. The preparations are utilized in both human and veterinary medicine. Suitable excipients include, e.g., organic and inorganic substances which are appropriate for enteral or parenteral administration, e.g., water, saline, tissue culture media, buffers, lysine, citrate, glycerol triacetate and other fatty acid glycerides, gelatin, soya lecithin, carbohydrates such as, mannitol, sucrose, lactose or starch, magnesium stearate, talc, cellulose or protein carriers, or a combination of the preceding compounds, such as mannitol/lysine, or mannitol/lysine/sucrose. The preparations are sterilized and/or contain additives, such as preservatives or stabilizers. For parenteral administration, e.g., systemic or local injection, a virus preparation is formulated, e.g., as an aqueous suspension or emulsion.

[0137] The invention also relates to a method of treating a disease in a mammal, in which the diseased cells have defects in an interferon-mediated antiviral response, comprising administering to the mammal a therapeutically effective amount of an interferon-sensitive, replication-competent, clonal virus. For example, cells infected with many viruses like hepatitis B that disable the interferon response are susceptible to the viruses of this invention. There is evidence that human immunodeficiency virus (HIV) disables the interferon response. The interferon-sensitive viruses of this invention are useful in treating such chronic virus infections such as those due to hepatitis B, hepatitis C, HIV, Epstein-Barr virus, human papilloma virus, and herpes virus.

[0138] The following examples are illustrative, but not limiting of the methods and compositions of the present invention. Other suitable modifications and adaptations of a variety of conditions and parameters normally encountered in clinical therapy which are obvious to those skilled in the art are within the scope of this invention.

Example 1

PPMK107, (a triple plaque purified isolate of the NDV strain MK107) demonstrates a selective cytotoxic activity toward many human cancer cells compared to normal human cells.

[0139] Human tumor cells and normal cells were grown to approximately 80% confluence in 24 well tissue culture dishes. Growth medium was removed and PPMK107 was added in 10 fold dilutions ranging from 10^6 plaque forming units (PFU)/well to 10^{-1} PFU/well. Controls wells with no virus added were included on each plate. Virus was adsorbed for 90 minutes on a rocking platform at 37°C. At the end of the incubation period, the viral dilutions were removed and replaced by 1 ml of growth medium. Plates were then incubated for 5 days at 37°C in 5% CO₂, then assessed qualitatively for the amount of cytopathic effect (CPE). Cytotoxicity was quantified by using a colorimetric MTT (2-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Cell Titer 96, catalog #G4000, Promega Corporation, Madison WI 53711) monitored at 570 nm, that detects mitochondrial enzyme activity (Mosman, T., 1983, J. Immunol. Methods 65:55). The viability in the virus treated wells was expressed as a percent of the activity in untreated control wells. The data was plotted graphically as PFU/well vs. viability as a percent of control. The IC₅₀ was calculated as the amount of virus in PFU/well causing a 50% reduction in the amount of viable cells.

[0140] The results are given in Tables 4, 5 and 6. PPMK107 demonstrated a high degree of cytotoxic activity against a diverse set of human cancer cells with 30 out of 39 malignant lines having an IC₅₀ value less than 1000 compared to the relative insensitivity of normal human cell types. The majority of human cancer cells had IC₅₀ values that were 2 to 3 orders of magnitude lower than most normal human cell types.

Table 4. Summary of Cytotoxicity Assay Results

TUMOR TYPE	CELL LINE	IC ₅₀ (PFU/well)
FIBROSARCOMA	HT1080	2
MELANOMA	SKMEL2	8
	SKMEL3	2
	SKMEL5	4
	A375	37
	MALM6-3M	778
	HT144	28
BREAST CARCINOMA	SKBR3	10
	MDA-MB-468	44
	ZR75-1	78
OVARIAN CARCINOMA	SW626	4
	PA-1	4
	ES-2	13
	SKOV-3	24
	OVCAR3	34
LUNG CARCINOMA (Large Cell, Low Passage)	H-1299	26
GLIOBLASTOMA	U87MG	25
	U373MG	765
	U138	38
	A172	207
BLADDER CARCINOMA	HT1197	3
	UM-UC-3	54
	HT1376	422
NEUROBLASTOMA	IMR32	41
CERVICAL CARCINOMA	HeLa	4
PROSTATE CARCINOMA	DU-145	31
	PC3	3.1 x 10 ³
COLON CARCINOMA	SW620	55
	HT29	> 1.0 x 10 ⁶
HEAD-AND-NECK CARCINOMA	KB	4
	A253	2.7 x 10 ³
	FaDu	2.9 x 10 ³
	Hep.2	1.5 x 10 ⁴
NEUROEPITHELIOMA	SK-N-MC	20
SMALL CELL CA, LUNG	DMS-114	48
	DMS-153	1.1 x 10 ⁵
	NCI-H345	1.2 x 10 ⁶
SMALL CELL CA, PROSTATE	NCI-H660	1.0 x 10 ⁵
LEUKEMIA (AML)	K562	5.4 x 10 ⁴

Table 5. Summary of Cytotoxicity Assay Results Using Normal Human Cells

CELL TYPE	CELL	IC ₅₀ (PFU/well)
Keratinocytes	NHEK	9.0 x 10 ⁶
Fibroblasts	CCD-922	1.4 x 10 ⁵
	NHDF	8.1 x 10 ³
Endothelial Cells	HPAEC	5.2 x 10 ⁴

(continued)

CELL TYPE	CELL	IC ₅₀ (PFU/well)
Renal Cells	RPTEC	2.7×10^4
Melanocytes	NHEM	5.1×10^4
Astrocytes	NHA	3.8×10^3

Table 6. Summary of Cytotoxicity Assay Results Using Rapidly Proliferating Normal Human Cells

CELL TYPE	RATE OF PROLIFERATION		IC ₅₀ (PFU/well)
	<i>IN VIVO</i>	<i>IN VITRO</i>	
Bone Marrow Cells	Moderate to High	High	62×10^3
CD34+ Enriched to 50%			
Breast Epithelial Cells	Very Low ¹	High ¹	30

¹ Human breast epithelial cells tested (HMEC) had a high rate of proliferation after stimulation with bovine pituitary extract and human epidermal growth factor. In marked contrast, normal breast epithelial cells almost always have a very low degree of proliferation in adult women with cancer.

Example 2**Use of PPMK107 for the Intratumoral Treatment of Human Tumor Xenografts (<10 mm and >5 mm) in Athymic Mice.**

[0141] Athymic mice were injected intradermally with 10 million human tumor cells. After tumors reached a size range from between 5 and 10 mm, a single injection of PPMK107 (at a dose of 3×10^8 PFU) or saline was given. Almost all tumor types exhibited a rate of complete or partial regression of 50% to 100% (see Table 7) in mice treated with PPMK107. The one exception is the case of the U87MG experiment (experiment I): Although only one of 9 tumors treated with PPMK 107 completely regressed, two more virus-treated tumors showed regression of 32% and 20% and two more virus-treated tumors had slower growth than all 8 tumors treated with saline control. Tumor regression was virtually absent in the saline control treated tumors: In all of these experiments (A through I listed in Table 7) only one of 73 control tumors showed regression. These results indicate that diverse tumor types showed responses to intratumoral PPMK107 treatment.

[0142] To examine virus replication within the tumor, immunohistochemical staining for viral antigen (using a monoclonal antibody against the NDV P protein) was performed using the subcutaneous HT1080 fibrosarcoma model. Within 30 minutes of intratumoral injection of 3×10^8 PFU of PPMK107, the tumor tissue was negative for viral antigen. However, by day 2 post treatment, intense immunostaining for viral antigen was seen within the tumor, indicating virus replication within the tumor. Importantly, virus replication was specific for the tumor tissue since the neighboring connective tissue and skin was negative for viral antigen.

Example 3**Use of PPMK107 for the Intravenous Treatment of Human Tumor Xenografts (<8.5 mm and >5.5 mm) in Athymic Mice.**

[0143] Athymic mice were injected intradermally with 10 million human HT1080 fibrosarcoma cells. After tumors reached a size range from between 5 and 8 mm, a intravenous injection(s) of PPMK107 or saline were made. As shown in Table 8, at the highest virus dose level (1×10^9 PFU) complete tumor regression was seen in all seven mice. Single injections of 3×10^8 and 6×10^7 resulted in regression rates of over 90%. While a single IV injection of 3×10^8 gave only a 55% rate of tumor regression, three IV injections at this dose level yielded a 100% rate of response. Mice treated with IV saline exhibited no evidence of tumor regression. These results indicate that subcutaneous HT1080 tumors are very responsive to IV treatment with PPMK107.

Table 7. PPMK107 intratumoral treatment of subcutaneous human tumor xenografts (<10 mm and > 5 mm) in athymic mice						
					Complete	Complete +
Tumor	Tumor Type	Expt #	Dose	N	Regression	partial Regression
HT1080	Fibrosarcoma	A	3.00E+08	12	11	11
		B	3.00E+08	9	8	8
		C	3.00E+08	8	8	
PA-1	Ovarian Carcinoma	D	3.00E+08	9	9	9
KB	Oral Carcinoma	E	3.00E+08	12	7	10
SKMEL5	Melanoma	F	3.00E+08	8	5	7
A375	Melanoma	G	3.00E+08	8	5	7
		H	3.00E+08	8	1	4
U87MG	Glioblastoma	I	3.00E+08	9	1	1

Table 8. PPMK107 Intravenous treatment of subcutaneous human HT1080 fibrosarcoma xenografts (< 8.5 mm and > 5.5 mm) in athymic mice.						
				Complete	Complete +	%
	Dose	Schedule	N	Regression	partial Regression	Regression
	1.00E+09	One Injection	7	7	7	100%
	3.00E+08	One Injection	10	9	10	100%
	6.00E+07	One Injection	11	10	10	91%
	2.00E+07	One Injection	11	5	6	55%
	2.00E+07	Three Injections	7	5	7	100%
		Every Other Day				
	Saline	One Injection	10	0	0	0%
	Saline	Three Injections	6	0	0	0%
		Every Other Day				

Example 4**First Experiment Using PPMK107 for Intratumoral Treatment of Large A375 Melanoma Xenografts in Athymic Mice**

[0144] Athymic mice were injected intradermally with 10 million A375 human melanoma cells. Ten days later, tumors of various sizes were treated with a single injection PPMK107 (doses of 3×10^8 , 9×10^8 , and 1.5×10^9 PFU) or saline. For those tumor with a single largest dimension of 10 to 11 mm, all nine completely regressed in response to intratumoral treatment with these doses of PPMK107, while of those tumors with a single largest dimension of 8 to 9.5 mm, twelve out of 24 completely regressed in response to virus therapy ($P < 0.008$; Table 9, section A). No tumor regression was seen in any mouse treated with saline.

[0145] These same tumors when sorted by tumor volume also indicated a high percentage of complete regression in those of larger tumor volume. In response to these doses PPMK107, complete regression occurred in 14 out of 17 tumors with volumes $>300 \text{ mm}^3$ (range of 304 to 397 mm^3) and in 7 out of 16 tumors with volumes $<300 \text{ mm}^3$ (range of 144 to 295; $P < 0.023$; Table 9, section B).

[0146] These results indicate that tumors at least 1 cm in length or 300 mm^3 in volume were at least as sensitive, if not more sensitive, to intratumoral PPMK107 treatment than smaller tumors.

Example 5**Second Experiment Using PPMK107 for Intratumoral Treatment of Large A375 Melanoma Xenografts in Athymic Mice.**

[0147] Tumors were established as in Example 4 ten days after tumor cell inoculation. Treatment consisted of various doses of PPMK 107 (3×10^6 PFU, 3×10^7 , 3×10^8 , and 1.5×10^9) or saline. For tumors 10 to 11.5 mm in single largest dimension, complete or partial (at least 50%) regression occurred in all 28 tumors treated with PPMK107 using these doses in contrast to no regression in any of the saline-treated mice (Table 10, section A).

[0148] When these same tumors were sorted by tumor volume, all 26 tumors greater than 300 mm^3 (range: 309 to 525 mm^3) regressed completely or partially (at least 50%) in response to PPMK107 in contrast to none of the saline treated mice (Table 10, section B).

[0149] These results confirm that tumors at least 1 cm in length or 300 mm^3 in volume are sensitive to intratumoral PPMK107 treatment.

Table 9: Intratumoral PPMK107 Treatment of Intradermal A375 Melanoma Xenografts									
A. Tumors Sorted Based on the Single Largest Dimension									
			Tumor Dimension: 8 to 9.8 mm			Tumor Dimension: 10 to 11 mm			
			Complete			Complete			
	Treatment	Dosage	N	Regression	%	N	Regression	%	
	PPMK107	1.5×10^9	8	2	25%	3	3	100%	
	PPMK107	9.0×10^8	8	7	88%	3	3	100%	
	PPMK107	3.0×10^8	8	3	38%	3	3	100%	
	Total		24	12	50%	9	9	100%	a
	Saline		6	0	0%	3	0	0%	

(continued)

B. Tumors Sorted Based on the Tumor Volume									
Tumor Volume: <300 mm ³					Tumor Volume: > 300 mm ³				
Complete					Complete				
Treatment	Dosage	N	Regression	%	N	Regression	%		
PPMK107	1.5x10 ⁹	6	2	33%	5	3	60%		
PPMK107	9.0x10 ⁸	4	3	75%	7	7	100%		
PPMK107	3.0x10 ⁸	6	2	33%	5	4	80%		
Total		16	7	44%	17	14	82%	<i>b</i>	
Saline		8	0	0%	1	0	0%		
a. P < 0.008 for complete regression in the PPMK107 10-11 mm group vs. the PPMK107 8-9.5 mm treated group									
b- P < 0.023 for complete regression in the PPMK107 treated >300 mm ³ group vs. the PPMK107-treated <300 mm ³ group									

Table 10: Intratumoral PPMK107 Treatment of Intradermal A375 Melanoma Xenografts.							
A. Tumors 10 to 11.5 mm (Sorted Based on the Single Largest Dimension)							
Regressions							
Treatment	Dose	N	Complete	%		Complete + Partial	%
	1.5 x 10 ⁸	7	7	100%		7	100%
	3.0 x 10 ⁸	7	6	86%		7	100%
	3.0 x 10 ⁷	7	5	71%		7	100%
	3.0 x 10 ⁶	7	5	71%		7	100%
	All PPMK107 Groups	28	23	82%		28	100%
	Saline	6	0	0%		0	0%
B. Tumors > 300 mm ³ (Sorted Based on the Tumor Volume)							
Regressions							
Treatment	Dose	N	Complete	%		Complete + Partial	%

(continued)

B. Tumors > 300 mm ³ (Sorted Based on the Tumor Volume)							
Treatment	Dose	N	Regressions				
			Complete	%		Complete + Partial	%
	1.5x10 ⁸	7	7	100%		7	100%
	3.0x10 ⁸	7	6	86%		7	100%
	3.0x10 ⁷	6	4	67%		6	100%
	3.0x10 ⁶	6	4	67%		6	100%
	All PPMK107 Groups	26	21	81%		26	100%
	Saline	5	0	0%		0	0%

Example 6**Third Experiment Using PPMK107 for Intratumoral Treatment of Large A375 Melanoma Xenografts in Athymic Mice.**

[0150] Tumors were established as in Example 4 nineteen days after tumor cell inoculation. Intratumoral treatment consisted of various doses of PPMK107 (3 x 10⁸, 3 x 10⁶, 3 x 10⁵, 3 x 10⁴, 3 x 10³, 3 x 10² PFU) or saline. For tumors 12.5 to 14 mm in single largest dimension (volume range: 632 to 787 mm³; average volume 698 mm³), tumor regressions of at least 50% occurred in two out of three mice treated with 3 x 10⁸ PFU in contrast to no regression in both saline-treated mice (Table 11). Using the same dose of PPMK107 (3 x 10⁸ PFU) to treat tumors with a single largest dimension of 10 to 12 mm (volume range: 320 to 600 mm³; average volume: 411 mm³), seven of 8 mice exhibited regression of at least 25% (P<0.001 for regression of at least 25% compared to the saline treated mice which exhibited no regressions, Table 11). Regressions of at least 25% for tumors of length 10 to 12 mm tumors were also seen in mice treated with 3 x 10⁶ PFU, 3 x 10⁵ PFU, 3 x 10⁴ PFU, and 3 x 10³ PFU, but not for mice treated with 3 x 10² PFU or saline (Table 11).

[0151] These results confirm that tumors at least 1 cm in length or 300 mm³ in volume are sensitive to intratumoral PPMK107 treatment.

Example 7**Fourth Experiment Using PPMK107 for Intratumoral Treatment of Large A375 Melanoma Xenografts in Athymic Mice.**

[0152] Tumors of largest dimension 10 to 12 mm were established as in Example 4 thirteen days after tumor cell inoculation. Intratumoral treatment consisted of a single injection of 3 x 10⁸ PFU of PPMK107 or saline. Volumes of those tumors treated with PPMK107 ranged from 295 to 600 mm³ (average tumor volume of 437 mm³). Groups of mice in each treatment group were euthanized on days 0, 2, 3, 4, 7, and 14 for tumor histology. For those mice observed for a minimum of 4 days, eleven out of 12 mice treated with PPMK107 exhibited regression of at least 25% compared to none of 8 in the saline group (P<0.0001, Table 12). At 2 days after PPMK107 treatment, two tumors already exhibited signs of regression but the degree of regression was less than 25%.

Table 11: 3rd Experiment Using PPMK107 for the Intratumoral Treatment									
of A375 Melanoma Xenografts (at least 10 mm In size)									
5									
		<u>Size: 12.5 to 14 mm</u>							
10				<u>Regressions</u>			Total # of	%	
	Treatment	N	Volume Range	Avg Volume	Complete	Partial ^a	> 25% & < 50% ^b	Regressions ^c	Regressions ^c
15	3.0 E +08	3	632 to 787	698	1	1	0	2	67%
	Saline	2	717 to 860	788	0	0	0	0	0%
20									
		<u>Size; 10 to 12 mm</u>							
25				<u>Regressions</u>			Total # of	%	
	Treatment	N	Volume Range	Avg Volume	Complete	Partial ^a	> 25% & < 50% ^b	Regressions ^c	Regressions ^c
30	3.0 E +08	8	320 to 600	411	0	3	4	7	88% <i>d</i>
	3.0 E +06	8	425 to 662	502	0	0	2	2	25%
35	3.0 E +05	8	245 to 600	421	0	0	1	1	13%
	3.0 E +04	8	336 to 600	477	0	0	1	1	13%
40	3.0 E +03	8	281 to 542	349	2	0	0	2	25%
	3.0 E +02	8	281 to 662	372	0	0	0	0	0%
45	Saline	8	379 to 666	518	0	0	0	0	0%
50									
55	<i>a</i> - Partial Regression Is defined as regression less than 100% and equal to or greater than 50%.								
	<i>b</i> - "Regression >25% & < 50%" is defined astumor regression greater than 25% and less than 50%.								

EP 1 032 269 B1

(continued)

				<u>Regressions</u>			Total # of	%	
5	Treatment	N	Volume Range	Avg Volume	Complete	Partial ^a	> 25% & < 50% ^b	Regressions ^c	Regressions ^c
10	c - Includes all tumor regression that is greater than 25%.								
	d - P < 0.001 for Regression greater than 25% In the 3 E+08 group vs the saline group.								

15

	Table 12. 4th Experiment Using PPMK107 for the Intratumoral Treatment								
	of A375 Melanoma Xenografts (at least 10 mm in size)								
20									
	<u>Tumor Size: 10 to 12 mm</u>								
25		<u>Day Euthanized</u>		<u>Regressions</u>			Total # of	%	
	Treatment	Post Treatment	N	Complete	Partial ^a	> 25% & < 50% ^b	Regressions ^c	Regressions ^c	
30	3.0 E +08	14 Days	3	0	2	1	3	100%	
	3.0 E +08	7 Days	3	0	2	1	3	100%	
	3.0 E +08	4 Days	3	0	2	1	3	100%	
	3.0 E +08	3 Days	3	0	0	2	3	67%	
35	3.0 E +08	All PPMK107 Groups	12	0	6	5	11	92%	d,e
40	Saline	14 Days	2	0	0	0	0	0%	
	Saline	7 Days	2	0	0	0	0	0%	
	Saline	4 Days	2	0	0	0	0	0%	
45	Saline	3 Days	2	0	0	0	0	0%	
	Saline	All Saline Groups	8	0	0	0	0	0%	
50									
	a - Partial Regression Is defined as regression less than 100% and equal to or greater than 50%.								
55	b - *Regression >25% & < 50% is defined as tumor regression greater than 25% and less than 50%.								

(continued)

	Day Euthanized		Regressions			Total # of	%	
5	Treatment	Post Treatment	N	Complete	Partial ^a	> 25% & < 50% ^b	Regressions ^c	Regressions ^c
	c - Includes Regression that is at least 25%.							
10	d - P < 0.03 for Complete or Partial Regression in the PPMK107. group of 12 mice vs the saline group of 8 mice.							
	e - P < 0.0001 for Regression at least 25% In the PPMK107 group of 12 mice vs							
	the saline group of 8 mice.							

Example 8**Fifth Experiment Using PPMK107 for Intratumoral Treatment of Large A375 Melanoma Xenografts in Athymic Mice.**

[0153] Tumors of largest dimension 10 to 12 mm were established as in Example 4 twenty days after tumor cell inoculation. Intratumoral treatment consisted of a single injection of 3×10^8 PFU of PPMK107 or saline. Volumes of those tumors treated with PPMK107 ranged from 361 to 756 mm³ (average tumor volume of 551 mm³). Nine out of 10 mice treated with PPMK107 exhibited a regression of at least 25% compared to none of 10 in the saline group (P<0.0001, Table 13).

Example 9**First Experiment Using PPMK107 for Intravenous Treatment of Large HT1080 Fibrosarcoma Xenografts.**

[0154] Athymic mice were injected subcutaneously with 10 million HT1080 human fibrosarcoma cells. Six days later, tumors were treated with a single injection PPMK107 (at a dose of 1.5×10^9 PFU) or saline. For those tumors 10 to 11 mm in single largest dimension, five out of six tumors completely or partially regressed in response to a single intravenous injection of PPMK 107 compared to none of the saline treated tumors (Table 14, P < 0.025). These results indicate that tumors at least 1 cm in length are sensitive to intravenous PPMK107 treatment.

Table 13: 5th Experiment Using PV701 for the Intratumoral Treatment							
of A375 Melanoma Xenografts (at least 10 mm in size)							
	Size: 10 to 12 mm						
		Regressions			Total # of	%	
45	Treatment	N	Complete	Partial ^a	>25% & <50% ^b	Regressions ^c	Regressions ^c
	3.0 E +08	10	0	4	5	9	90% d,e
	Saline	10	0	0	0	0	0%
50							
	a - Partial Regression is defined as regression less than 100% and equal to or greater than 50%.						
	b - "Regression >25% & < 50%" is defined as tumor regression greater than 25% and less than 50%.						
55	c - Includes all tumor regression that is at least 25%.						
	d - P < 0.05 for Complete or Partial Regression in the PV701 group of vs the saline group.						

(continued)

	Size: 10 to 12 mm						
		Regressions			Total # of	%	
Treatment	N	Complete	Partial ^a	>25% & <50% ^b	Regressions ^c	Regressions ^c	
e - P < 0.0001 for all tumor regression at least 25% in the PV701 group vs the saline group.							

Table 14: Intravenous Treatment of Subcutaneous HT1080									
Human Fibrosarcoma Xenografts In Athymic Mice									
	Size: 10 to 11 mm								
				Regressions					
Treatment	Dose	N		Complete	%		Complete + Partial	%	
PPMK107	1.5E+09	6		4	67%		5	83%	a
Saline		4		0	0		0	0	
a- P < 0.025 (by Fisher's exact test) for complete or partial regression (at least 50% regression) In the									
PPMK107 treated group compared to the saline group									

Example 10**Specific Clearing of PPMK107 Infection from Normal but Not Tumor Cells.**

[0155] In order to examine the mechanism of tumor-specific killing by NDV strain PPMK107, representative tumor cells were chosen based on the following criteria: a) ability to form tumors as xenografts in athymic mice; b) the tumor xenografts are specifically killed in vivo following administration of PPMK107; c) the tumors cells exhibit killing by PPMK107 in vitro at virus concentrations that are several logs below the concentration to kill resistant, normal cells; and d) tumor cells must be easily distinguished from the normal cells when present as a co-culture. Xenograft tumors comprised of KB head and neck carcinoma cells exhibit 83% complete or partial regression in response to a single intratumoral injection of PPMK107, are more than four logs more sensitive to killing by PPMK107 in vitro than are normal primary skin fibroblasts (CCD922-sk), and are easily distinguished from CCD922-sk cells when present as a co-culture.

[0156] Accordingly, co-cultures of KB and CCD922-sk cells were infected at a multiplicity of infection (m.o.i., the ratio of virus added per cell) of 0.0005 and the course of the infection followed for 5 days by immunohistochemical staining for a viral antigen (NDV P protein). Infection of normal cells peaked at 2 days with little or no apparent cell death as determined by visual inspection of the cell monolayer. On the third day post-infection the amount of viral expression in the normal cells decreased significantly, while infection of the tumor cells was clearly apparent. The amount of viral antigen virtually disappeared in the normal cells on days 4 and 5, while the infection in the tumor cells progressed rapidly through the tumor cell population resulting in destruction of the majority of the tumor cells present in the co-culture.

[0157] Thus, normal cells were infected and easily cleared the infection in a manner consistent with the anti-viral effects of IFN. The tumor cells were unable to establish an anti-viral state in response and were killed by the unabated viral growth, despite the presence of physiologically effective concentrations of IFN secreted into the media by the normal cells.

Example 11**Demonstration that Interferon is an Important Component of Viral Clearing in Normal CCD922-sk Cells.**

5 [0158] The hypothesis that interferon was mediating the ability of CCD922-sk cells to clear the infection of PPMK107 was tested. Polyclonal neutralizing antibodies to human interferon- α or human interferon- β , used alone or in combination, were added daily to cultures of CCD922-sk cells infected with PPMK107 at an moi of 0.0005 and the progress of the infection followed for three days. The amount of viral antigen present in the cells increased in proportion to the concentration of neutralizing antibody, with the effect of the anti-interferon- β antibody being more marked than that of the anti-interferon- α antibody; consistent with reports that fibroblasts produce predominantly the beta form of interferon.

10 [0159] The ability to make the normally insensitive cells more susceptible to infection with PPMK107 through the addition of neutralizing antibody to interferon supports the hypothesis that a key difference between the sensitivity of normal and tumor cells to killing by PPMK107 lies in the ability of normal cells, but not tumor cells, to establish an interferon-mediated anti-viral response.

15

Example 12**Demonstration that Interferon- β is an Important Component of Viral Clearing in Other Normal Cells.**

20 [0160] In this experiment, it was determined that another normal cell (NHEK, normal human epithelial cells) known to be quite resistant to killing by PPMK107, was made more sensitive through the addition of polyclonal anti-interferon- β antibody to a culture of infected cells. NHEK (normal human epithelial keratinocyte) cells were infected at an moi of either 0.0005 or 0.05 and had antibody added daily over five days.

25 [0161] In the cultures infected at the low moi (0.0005), antibody dependent augmentation of viral antigen expression was clear at five days post-infection, but was less clear earlier in the experiment. Antibody addition to cultures infected with PPMK 107 at an moi of 0.05 resulted in a marked increase in viral antigen at 4 and 5 days post-infection. At 2 and 3 days post-infection the addition of neutralizing antibody resulted in less accumulation of viral antigen (Fig. 1).

30 [0162] The culture supernatants from the high moi samples were also titrated for the amount of infectious virus present by plaque assay on human HT1080 fibrosarcoma tumor cells; the standard assay system in our laboratory. Results from this analysis demonstrated that at five days post-infection there was 19-fold increase in the amount of infectious virus in the antibody-treated cultures relative to mock-treated controls (Fig. 1).

[0163] These results suggest a general mechanism by which normal cells are protected from killing by PPMK 107 through an interferon-related mechanism.

35 **Example 13****Comparison of the Effect of Interferon- β on PPMK107 Infection in Tumor and Normal Cells.**

40 [0164] A comparison of the effect of exogenously added interferon- β on the infection of normal (CCD922-sk) and tumor cells of high (KB) or intermediate (HEp2) sensitivity PPMK107 was performed. Separate cultures of the three cells were treated with interferon- β at 20, 200, or 2000 units/ml 1 day pre- and 2 days post-infection at an moi of 0.0005.

45 [0165] At 3 days post-infection the low level of viral antigen expression present in the normal cells was eliminated at all doses of interferon used. Conversely, the addition of interferon to the highly sensitive KB tumor cells at concentrations of 2 or 200 units/ml decreased relative levels of viral antigen expression 2-fold, with complete suppression at 1000 units/ml interferon. The intermediately sensitive HEp-2 cells responded to the exogenous interferon by clearing viral antigen expression at all of the interferon doses used (Fig. 2).

50 [0166] The pattern of sensitivity in the KB and CCD922-sk cells to the anti-viral effects of exogenously added interferon- β was inversely proportional to the sensitivity of these cells to killing by PPMK 107. The ability of the HEp-2 cells to respond to the effects of interferon indicates that these cells are able to efficiently utilize the concentrations of interferon used in this experiment. Similarly, the response of the KB cells to the high doses of interferon suggests that the inability to establish an interferon-mediated anti-viral response does not result from an absolute defect in the interferon pathway, but rather a relative insensitivity compared to normal cells.

55 **Example 14****Effect of Low Concentrations of Interferon- β on the Infection of Normal and Tumor Cells by PPMK107.**

[0167] In this experiment normal (CCD922-sk) and tumor (KB) cells were treated with low concentrations of interferon-

β (0.2, 2, and 20 units/ml) 1 day before and 2 days post-infection with PPMK 107 at an moi of 0.05.

[0168] Under these conditions the normal cells experienced a dose-dependent decrease in the amount of viral antigen, while the relative levels of viral antigen in the tumor cells was unaffected by the addition of exogenous interferon (Fig. 3).

5 **Example 15**

PPMK107 Purification

Method A

10 [0169] PPMK107 was derived from the mesogenic Newcastle disease virus strain Mass-MK107 by triple plaque purification. Approximately 1000 PFUs (plaque forming units) of live PPMK107 were inoculated into the allantoic fluid cavity of each 10 day old embryonated chicken egg. After incubation at 36°C for 46 hours, the eggs were chilled and then the allantoic fluid was harvested. Cells and cell debris were removed from the allantoic fluid by centrifugation at
15 1750 x g for 30 minutes. The clarified allantoic fluid (supernatant containing virus) was then layered over a 20%/55% discontinuous sucrose gradient) and centrifuged at approximately 100,000 x g for 30 minutes. The purified virus was harvested from the 20%/55% interface and dialyzed against saline to remove the sucrose.

Method B

20 [0170] In another advantageous embodiment, the clarified allantoic fluid was frozen at -70°C. After thawing, the fluid was maintained at 1 to 4°C overnight and then the contaminating material was removed from the virus suspension by means of centrifugation (1750 x g for 30 minutes). This material was further processed using the discontinuous sucrose gradient on the ultracentrifuge as above.

Method C

25 [0171] In another advantageous embodiment, ultracentrifugation on the discontinuous sucrose gradient was accomplished by means of a continuous flow ultracentrifuge.

Method D

30 [0172] In another advantageous embodiment, harvested allantoic fluid is diluted with a buffer containing 5% mannitol and 1.0% 1-lysine, pH 8.0 (ML buffer) and is clarified and exchanged with ML buffer by tangential flow filtration (TFF) through filters with a nominal pore size of 0.45 μ m. The permeate containing the clarified virus in ML buffer is collected and virus is purified by TFF through filters with a nominal cut-off of 300,000 daltons in ML buffer. The concentrated, purified virus in ML buffer is collected as the retentate from this step and is again diluted with ML buffer before being applied to a Sephacryl S500 (Pharmacia) gel permeation column equilibrated with ML buffer. Fractions containing purified virus are collected, pooled and can be reconcentrated by TFF through filters with a nominal cut-off of 300,000 daltons
40 with ML buffer.

Results

*** Clonal Virus**

45 [0173] After generation of PPMK107 by plaque purification, eight individual molecular clones from the population of virions were found to have an identical sequence (e.g., a homology of 100%) of over 300 contiguous nucleotides within the fusion protein gene of NDV. PPMK107 is a clonal virus with a high degree of genetic homogeneity.

*** PFU/mg protein**

50 [0174] One quantitative means of measuring purity is by determination of a PFU/mg protein. Higher values indicate a greater level of purity. Using Method A, PFU/mg values of at least 4.8×10^{10} were achieved (see Table 15). Using Method C, PFU/mg protein values of at least 2.0×10^{10} were achieved. For a mesogenic strain of NDV, a literature value for this measurement of purity has not been found. The best estimate for a mesogenic strain of NDV is the virus preparation (NDV MassMK107, lot RU2, prepared as in Faaberg KS and Peebles, ME, 1988, J Virol 62:586; and Bratt, MA and Rubin, H. 1967, Virology 33:598-608). This RU2 lot was found to have a PFU/mg of 1.3×10^9 PFU/mg of protein. The purity values achieved by Method A are approximately 40 times better than what the Peebles method achieved (see
55

Table 15).

*** Particle per PFU Ratio**

[0175] Another quantitative means of measuring purity is by determination of a ratio of particles per PFU. Lower values indicate a greater level of purity. Particle counts were done by electron microscopy using standard methods. Using either Method A or Method B, particles per PFU values near one were achieved (Table 15).

Table 15. Virus Purity

Virus Preparation Method	Virus	Lot#	PFU per mg protein	Particle per PFU
Preferred Method A	PPMK107	L2	4.8 x 10 ¹⁰	0.80
		L4	6.9 x 10 ¹⁰	NT ^a
		L5	6.6 x 10 ¹⁰	NT
		L6	7.7 x 10 ¹⁰	0.55
		L7	6.1 x 10 ¹⁰	NT
Preferred Method C	PPMK107	D004	2.0 x 10 ¹⁰	0.32
		D005	4.5 x 10 ¹⁰	0.52
		D010	4.4 x 10 ¹⁰	NT
Preferred Method D	PPMK107	RD2	5.6 x 10 ¹⁰	NT
		RD3	5.0 x 10 ¹⁰	NT
^a NT, Not Tested				

[0176] Virus preparations using Methods A and C also permitted purification of NDV to a level substantially free of contaminating egg proteins. For the PPMK107 lot 7 preparation using Method A, ovalbumin, was not detectable in a Western blot using (1) 1.7×10^9 PFU of purified virus per well (3.3 cm in width) run on an SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) gel (1 mm thick); (2) a nitrocellulose membrane for transfer; and (3) rabbit anti-ovalbumin (Cappel rabbit IgG fraction at a 1:200 dilution of a 4 mg/ml antibody concentration). For PPMK107 preparations using Method D and analyzed by SDS-PAGE followed by silver staining, no band corresponding to ovalbumin was observed.

Example 16

Use of PPMK107 To Prevent Deaths from ES-2 Ovarian Carcinoma Ascites in Athymic Mice.

[0177] In this experiment, all of the athymic mice (female, NCR nu/nu, 8 weeks old) were given an intraperitoneal injection of 10^6 ES-2 cells. Seven days later before ascites had developed, they were treated intraperitoneally with saline or PPMK107 (at 1×10^9 PFU). As shown in Figure 4, there was a markedly improved survival in the animals treated with PPMK107 compared to saline. The majority of the mice in the saline treated group had developed ascites by seven days post-treatment and by day 38, all of these animals had died. In marked contrast, 92% of the mice treated with PPMK107 were still alive by day 38 and 25% of these animals were long term survivors (> 120 day survival).

Example 17

PPMK107 Treatment of ES-2 Ovarian Carcinoma in Athymic Mice When Ascites is Present.

[0178] In this experiment, all of the athymic mice (female, NCR nu/nu, 8 weeks old) were given an intraperitoneal injection of 10^6 ES-2 cells. Fourteen days later when the majority of mice had developed ascites, the mice without ascites were excluded and the mice with ascites were randomized into 7 intraperitoneal treatment groups (PPMK107- one treatment on day 0; PPMK107- two treatments for the first week; PPMK107- one treatment each week; PPMK107-two treatments each week; saline- one treatment on day 0; saline-two treatments for the first week; saline-two treatments each week). A dose of 1×10^9 PFU/mouse was used for each virus treatment. All of the mice before the first treatment and any additional treatments were drained of the ascites fluid. Day 0 refers to the day of first treatment.

[0179] The degree of ascites for each mouse was quantified and noted as follows:

Ascites Score	Degree of Ascites
1.0	Animal appears normal- little or no ascites present
2.0	Abdomen slightly distended; animal is capable of normal functions
3.0	Abdomen distended; animal is slow-moving, hunched with a staggered gait.
4.0	Abdomen completely distended; animal moribund
5.0	Death after ascites development

[0180] As shown in Table 16, all of the saline-treated animals had more advanced ascites than the PPMK 107-treated animals on both days 7 and 10. On day 7 post initial treatment, each the saline group had average ascites scores above 3.5 while all of the PPMK107-treated groups had average ascites scores at 3.0 or below. Similarly on day 10 post initial treatment, each the saline group had average ascites scores above 4.5 while all of the PPMK107-treated groups had average ascites scores at 4.1 or below. These results indicate that ascites fluid production was markedly decreased in virus-treated animals compared to saline controls.

Table 16. PPMK107 Treatment of ES-2 Ovarian Carcinoma in Athymic Mice When Ascites is Present.

Treatment	# of Mice	Average Ascites Score, Day 7	Average Ascites Score, Day 10
Saline x 1	12	4.3	4.7
Saline x2	12	3.7	4.6
Saline x2 each wk	12	4.3	4.8
PPMK 107 x 1	17	3.0	4.1
PPMK 107 x 2	17	2.3	3.6
PPMK 107 x 1 each wk	17	2.6	2.6
PPMK 107 x2 each wk	17	2.2	3.6

Example 18

Use of a Desensitizing Dose of PPMK107 to Reduce the Lethality of a Subsequent Dose of PPMK107.

[0181] C57BL/6 mice (seven weeks old) were injected intravenously on day 0 with either saline or a desensitizing dose of PPMK107 (3×10^8 PFU/mouse). Two days later each set of mice were further subdivided into groups for intravenous dosing with saline or PPMK107 (at doses of 1×10^9 , 2.5×10^9 , 5×10^9 , and 1×10^{10} PFU/mouse). As shown in Table 17, when saline was used to pretreat the mice, deaths were recorded in the mice subsequently dosed with 2.5×10^9 , 5×10^9 , and 1×10^{10} PFU. The doses of 5×10^9 and 1×10^{10} PFU were 100% lethal to the mice pretreated with saline. In contrast, no deaths were seen in any group of mice given a desensitizing dose of PPMK107 on day 0 followed by PPMK107 injection two days later at dose levels up to 1×10^{10} PFU. These data indicate that PPMK107 can be used to prevent the lethality of subsequent dosing with this same agent. Furthermore, the maximal tolerated dose of PPMK107 can be raised by an approximate order of magnitude when using this virus as a desensitizing agent.

Table 17. Use of a Desensitizing Dose of PPMK107 to Reduce the Lethality of a Subsequent Dose of PPMK107.

Group	Injection on Day 0	Dose on Day 2	# of Mice	# of Deaths	% Lethality
1	Saline	Saline	8	0	0
2	Saline	PPMK107, $1.0\text{E}+09$	8	0	0
3	Saline	PPMK107, $2.5\text{E}+09$	8	3	38
4	Saline	PPMK107, $5.0\text{E}+09$	8	8	100
5	Saline	PPMK107, $1.0\text{E}+10$	8	8	100
6	PPMK107, $3\text{E}+08$	Saline	8	0	0

(continued)

Group	Injection on Day 0	Dose on Day 2	# of Mice	# of Deaths	% Lethality
7	PPMK107,3E+08	PPMK107,1.0E+09	8	0	0
8	PPMK107,3E+08	PPMK107,2.5E+09	8	0	0
9	PPMK107,3E+08	PPMK107,5.0E+09	8	0	0
10	PPMK107,3E+08	PPMK107,1.0E+10	8	0	0

Example 19**Slower Intravenous Injection Rate Reduces the Toxicity of PPMK107.**

[0182] Twenty two athymic mice (8 weeks old) were anesthetized with a combination of ketamine/xylazine and placed into a restrainer to help inhibit their movement during the injection process to allow for either a slow or rapid injection of PPMK107. For the slow injection group, 0.2 mL of 4×10^9 PFU of PPMK107 in saline was injected intravenously over a 4 minute period with 0.01 mL given every 10 to 15 seconds. The rapid injection group received the same dose and volume but over a 30 second period. As shown in Table 18, the animals receiving their dose of PPMK107 over 4 minutes had half as much maximal weight loss (recorded on day 2 after dosing) as the animals receiving the same IV dose over 30 seconds. These results indicate that PPMK107 has less toxicity and is safer for intravenous administration when injected at such slower rates.

Table 18. Slower IV Injection of PPMK107 Results in Reduced Toxicity.

Group	Length of Time That Dose was Administered	# of Mice	Maximal Percent Weight Loss
Rapid Injection of 4E+09	30 seconds	11	12%
Slow Injection of 4E+09	4 minutes	11	6%

Example 20**Use of PPMK107 in the Treatment of Patients with Advanced Cancer.**

[0183] PPMK107 has been tested in a phase I clinical trial in the U.S.A. by the intravenous route. Twenty-three patients with advanced solid tumors, no longer amenable to established therapies, have been treated with PPMK107. Seventeen of these patients have received a single dose for the initial treatment course. Six other patients are receiving three doses per week for one week for the initial treatment course. The sizes of each patient's tumors were followed once per month. Patients with at least stable disease (less than 25% increase and less than 50% decrease in the sum of the products of all measurable tumors in the absence of any new lesions) were eligible for additional treatment courses each month.

Regression of a Palpable Tumor

[0184] A 68 year old female with colon carcinoma had a palpable abdominal tumor among her widespread metastases. After a single IV treatment with PPMK107, this patient experienced a 91% regression of this single abdominal wall tumor over the course of two weeks (Table 19). Measurements of the tumor one day after dosing (3.75 x 3 cm) were similar to the baseline measurements of 4 x 3 cm. However, by day 7 post dosing, the tumor had decreased in size to 2 x 2 cm and continued to decrease in size to 1.5 x 1.5 cm by day 14 after PPMK 107 dosing. Previous to PPMK 107 treatment, this tumor mass had been rapidly growing with a 1065% increase in tumor volume in the two weeks before PPMK 107 dosing. This patient went off study because of increased growth of the tumor elsewhere.

Table 19. Size of Palpable Abdominal Wall Tumor in Patient #123 (68 year old Female with Metastatic Colon Carcinoma) After a Single IV pPMK107 Dose of 12 Billion PFU/m².

Date	Time After Dosing	Tumor Dimensions (L x W, cm ³)	Tumor Volume (0.5 x L x W x W, cm ³)	% Reduction in Tumor Volume
7/23/98	Day 0	4 x 3	18.	-

(continued)

Date	Time After Dosing	Tumor Dimensions (L x W, cm ³)	Tumor Volume (0.5 x L x W x W, cm ³)	% Reduction in Tumor Volume
7/24/98	Day 1	3.75 x 3	16.9	6%
7/30/98	Day 7	2 x 2	4.0	78%
8/6/98	Day 14	1.5 x 1.5	1.7	91%

Stabilization of Cancer

[0185] Eight other patients, all of whom previously had tumor progression with conventional cancer therapies, experienced benefit in the form of stabilization of their advanced cancer after PPMK107 dosing. These patients with stable disease represent those with diverse types of cancer including renal cancer, pancreatic cancer, breast cancer and lung cancer. After three months of PPMK107 treatment, a 67 year old man with advanced and widely metastatic renal cancer currently had stable disease with no indications of any new growth and no indication of an increase in tumor size. There has been a higher rate for stable disease benefit with higher doses of PPMK 107: Two out of 6 patients with stable disease (33% of patients) at the first two single dose levels (5.9 and 12 billion PFU per m²) and 4 out of 5 patients (80% of patients) with stable disease at the highest single dose level (24 billion PFU per m²) (Table 20).

Table 20. Treatment of Patients with Advanced Cancer with PPMK107.

Dose Level (Billion PFU per m ²)	# of Patients Treated at this Dose Level	# of Patients with Stable Disease	% of Patients with Stable Disease	Types of Cancer with Stable Disease for at Least One Month & Length of Stable Disease
5.9	6	2	33%	Renal Cancer- Ongoing 3 months Lung Cancer- Ongoing 2 months
12	6	2	33%	Pancreatic Cancer- Ongoing 2 months Ovarian Cancer- Ongoing 1 month
24	5	4	80%	Breast Cancer- Ongoing 1 month Breast Cancer- Ongoing 1 month Lung Cancer- Ongoing 1 month Pancreatic Cancer- Ongoing 1 month
Total	17	8	47%	Noted Above.

Reduction in Pain Medication

[0186] One patient at the single dose 5.9 billion PFU/m² dose level benefited from PPMK107 treatment in the form of symptomatic relief of cancer pain as denoted by a reduction in narcotic pain medication.

Desensitization

[0187] A clear desensitizing effect from the first dose (at 5.9 billion PFU/m²) is seen on subsequent doses (also at 5.9 billion PFU/m²) within the same week. In general, the reported side effects from second and third doses have been

much less. For example, the first 4 patients in this multidose treatment regimen (three doses per week for one week) had fever after the first dose in spite of receiving prophylactic antipyretic treatment with acetaminophen and ibuprofen. The majority of these patients had no fever after receiving the second and third doses, even in cases in which they did not receive antipyretics. This indicates that administration of the first dose in the three times per week schedule reduces the toxicity for the second and third doses.

Dosing Through Neutralizing Antibodies in Serum

[0188] Using the dose range in this phase I study (≥ 5.9 billion PFU/m²), there is also clear indication that one can effectively deliver virus to patients even if they have generated neutralizing antibodies. A 72 year old woman with pancreatic cancer at the 12 billion PFU/m² single dose level has had stable disease for 2 months since beginning PPMK 107 treatment. A second course (consisting of a single IV dose of PPMK107) was administered one month after the first dose when the patient had produced neutralizing antibodies in her serum. Seven days after this second course, her urine was positive for PPMK107 at a titer of at least 40 PFU per mL. This result indicates that the neutralizing antibodies to PPMK 107 in this patient's serum was not able to completely inhibit the virus with a second treatment course.

Example 21

Summary of Cytotoxicity Assay Results with Newcastle Disease Virus PPNJROAKIN

[0189] Human tumor cells and normal cells were grown to approximately 80% confluence in 24 well tissue culture dishes. Growth medium was removed and PPNJROAKIN, a plaque purified clone of the mesogenic Newcastle disease virus strain New Jersey Roakin-1946, was added in 10 fold dilutions ranging from 10⁷ plaque forming units (PFU)/well to 1 PFU/well. Controls wells with no virus added were included on each plate. Virus was adsorbed for 90 minutes on a rocking platform at 37°C. At the end of the incubation period, the viral dilutions were removed and replaced by 1 ml of growth medium. Plates were then incubated for 5 days at 37°C in 5% CO₂. Cytotoxicity was quantified by using a colorimetric MTT (2-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Cell Titer 96, catalog #G4000, Promega Corporation, Madison WI 53711) monitored at 570 nm, that detects mitochondrial enzyme activity (Mosman, T., 1983. J. Immunol. Methods 65:55). The viability in the virus treated wells was expressed as a percent of the activity in untreated control wells. The data was plotted graphically as PFU/well vs. viability as a percent of control. The IC₅₀ was calculated as the amount of virus in PFU/well causing a 50% reduction in the amount of viable cells.

Table 21. Summary of Cytotoxicity Assay Results with PPNJROAKIN.

Cell Type	Cell Line	IC ₅₀ (PFU/well)
Fibrosarcoma	HT1080	13.8
Head and Neck Carcinoma	KB	2.4
Normal Fibroblast	CCD922sk	1.2 x 10 ⁴

[0190] These results (Table 21) show that PPNJROAKIN demonstrates tumor-selective killing of at least two different human tumor cells (HT1080 and KB) relative to normal skin fibroblasts. The IC₅₀ values for the two tumor cell lines are between 800 and 5000-fold lower than that for normal cells.

Example 22

Summary of Cytotoxicity Assay Results with Newcastle Disease Virus PPCONN70726

[0191] Human tumor cells and normal cells were grown to approximately 80% confluence in 24 well tissue culture dishes. Growth medium was removed and PPCONN70726, a plaque purified clone of the mesogenic Newcastle disease virus strain Connecticut 70726-1946, was added in 10 fold dilutions ranging from 10⁷ plaque forming units (PFU)/well to 1 PFU/well. Controls wells with no virus added were included on each plate. Virus was adsorbed for 90 minutes on a rocking platform at 37°C. At the end of the incubation period, the viral dilutions were removed and replaced by 1 ml of growth medium. Plates were then incubated for 5 days at 37°C in 5% CO₂. Cytotoxicity was quantified by using a colorimetric MTT (2-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Cell Titer 96, catalog #G4000, Promega Corporation, Madison WI 53711) monitored at 570 nm, that detects mitochondrial enzyme activity (Mosman, T., 1983, J. Immunol. Methods 65:55). The viability in the virus treated wells was expressed as a percent of the activity

in untreated control wells. The data was plotted graphically as PFU/well vs. viability as a percent of control. The IC₅₀ was calculated as the amount of virus in PFU/well causing a 50% reduction in the amount of viable cells.

Table 22. Summary of Cytotoxicity Assay Results with PPCONN70726.

Cell Type	Cell Line	IC ₅₀ (PFU/well)
Head and Neck Carcinoma	KB	18.1
Glioblastoma	U87MG	12.7
Glioblastoma	U373MG	879
Normal Fibroblast	CCD922sk	7.3 x 10 ⁴

[0192] These results (Table 22) show that PPCONN70726 demonstrates tumor-selective killing of at least three different human tumor cells (KB, U87MG, and U373MG) relative to normal skin fibroblasts. The IC₅₀ values for the two tumor cell lines are between 80 and 5000-fold lower than that for normal cells.

Example 23

Intratumoral Treatment of HT1080 Fibrosarcoma Xenografts in Athymic Mice Using PPMK107, PPNJROAKIN, or PPCONN70726.

[0193] In this experiment, athymic mice (female, NCR nu/nu, 5 to 6 weeks old) received a subcutaneous injection of 10⁷ HT1080 tumor cells. Four days later when tumors reached a size range of 6 to 8.5 mm, mice were treated intratumorally with saline, PPMK107 (at 1 × 10⁸ PFU), PPNJROAKIN (at 1 × 10⁸ PFU), or PPCONN70726 (at 1 × 10⁸ PFU). As shown in Table 23, tumor regression was noted in mice treated with these three viruses (PPMK107, PPNJROAKIN, and PPCONN70726). After PPMK107 treatment of 12 mice, four experienced complete tumor regression and six experienced partial regression. After PPNJROAKIN treatment of 12 mice, one mouse experienced complete tumor regression and two experienced partial regression. After PPCONN70726 treatment of 12 mice, three experienced complete tumor regression and two experienced partial regression. No tumor regression was noted in any of the animals treated with saline. These results show that the three mesogenic strains of NDV can cause tumor regression.

Table 23. Regression of HT1080 Fibrosarcoma Tumors in Athymic Mice after Treatment with One of Three Viruses (PPMK107, PPNJROAKIN and PPCONN70726) Each at a Dose of 1 x 10⁸ PFU.

Treatment	# of Mice	Regression		
		Partial (PR)	Complete (CR)	PR + CR (%)
PPMK107	12	6	4	10 (83%)
PPNJROAKIN	12	2	1	3 (25%)
PPCONN70726	12	2	3	5 (42%)
Saline	11	0	0	0 (0%)

Example 24

Effects of PPMK107, PPNJROAKIN, PPCONN70726 after Intracerebral Injection in Immunodeficient Athymic (nu/nu) and Immunocompetent Heterozygote (nu/+) Mice.

[0194] Fifty-six athymic mice (nu/nu) and 56 immunocompetent heterozygote (nu/+) mice were given stereotaxic intracerebral injections with either saline, PPMK107, PPNJROAKIN, or PPCONN70726. Eight additional mice of each type were used as untreated controls. Viruses were used at one of two dose levels (2 x 10⁴ or 3.5 x 10⁶ PFU/mouse). As shown in Table 24, all of the heterozygote nu/+ mice treated with each of the three viruses at the two dose levels survived through day 39 with the exception of one mouse at the lower PPCONN70726 dose level that was euthanized for non-neurological symptoms. Athymic nu/nu animals treated with either PPMK107 or PPCONN70726 had significantly less survival than the heterozygotes. This was especially true for the highest PPMK107 or PPCONN70726 virus dose of 3.5 x 10⁶ PFU/mouse where only 13% (1 of 8) of the athymic animals in each virus group survived through day 39. In contrast, there was 75% survival of the PPNJROAKIN-treated athymic mice at this same dose level (3.5 x 10⁶ PFU/

mouse). These data indicate that PPNJROAKIN is better tolerated in the brains of athymic mice than the other two virus strains.

Table 24. Survival of Mice Following Intracerebral Injection of PPMK107, PPCONN70726, and PPNJROAKIN.

5		Intracranial Injection	# of Mice	% Survival at Day 39
	nu/+	Untreated	8	100
	nu/+	Saline	8	100
10	nu/+	PPMK107, 2E+04	8	100
	nu/+	PPMK107, 3.5E+06	8	100
	nu/+	PPCONN70726, 2E+04	8	88 *
	nu/+	PPCONN70726, 3.5E+06	8	100
15	nu/+	PPNJROAKIN, 2E+04	8	100
	nu/+	PPNJROAKIN, 3.5E+06	8	100
20	nu/nu	Untreated	8	100
	nu/nu	Saline	8	100
	nu/nu	PPMK107, 2E+04	8	75
	nu/nu	PPMK107, 3.5E+06	8	13
25	nu/nu	PPCONN70726, 2E+04	8	75
	nu/nu	PPCONN70726, 3.5E+06	8	13
	nu/nu	PPNJROAKIN, 2E+04	8	100
30	nu/nu	PPNJROAKIN, 3.5E+06	8	75
* - The one non-surviving mouse in this treatment group was euthanized for non-neurological symptoms.				

Example 25

Summary of Cytotoxicity Assay Results with Sindbis Virus PPSINDBIS-Ar339

[0195] Human tumor cells and normal cells were grown to approximately 80% confluence in 24 well tissue culture dishes. Growth medium was removed and PPSINDBIS-Ar339, a plaque purified clone of Sindbis Ar-339 was added in 10 fold dilutions ranging from 10^7 plaque forming units (PFU)/well to 1 PFU/well. Controls wells with no virus added were included on each plate. Virus was adsorbed for 90 minutes on a rocking platform at 37°C. At the end of the incubation period, the viral dilutions were removed and replaced by 1 ml of growth medium. Plates were then incubated for 5 days at 37°C in 5% CO₂. Cytotoxicity was quantified by using a colorimetric MTT (2-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Cell Titer 96, catalog #G4000, Promega Corporation, Madison WI 53711) monitored at 570 nm, that detects mitochondrial enzyme activity (Mosman, T., 1983, J. Immunol. Methods 65:55). The viability in the virus treated wells was expressed as a percent of the activity in untreated control wells. The data was plotted graphically as PFU/well vs. viability as a percent of control. The IC₅₀ was calculated as the amount of virus in PFU/well causing a 50% reduction in the amount of viable cells.

Table 25. Summary of Cytotoxicity Assay Results with PPSINDBIS-Ar339.

Cell Type	Cell Line	IC ₅₀ (PFU/well)
Pancreatic Carcinoma	Panc-1*	69
Colorectal Carcinoma	SW620*	13
Colorectal Carcinoma	SW1463	1.8×10^5
Non-small cell Lung carcinoma	A427	$> 1 \times 10^6$

(continued)

Cell Type	Cell Line	IC ₅₀ (PFU/well)
Non-small cell Lung carcinoma	A549	5.2 x 10 ⁴
Renal carcinoma	A498	2.4 x 10 ⁴
Renal carcinoma	Caki-1	3.4 x 10 ⁴
Fibrosarcoma	HT1080	7.4 x 10 ⁵
Normal Keratinocyte	NHEK	2.0 x 10 ⁵
Normal Fibroblast	CCD922sk	1.6 x 10 ⁵
* Cells known to overexpress the mRNA for the high affinity laminin receptor.		

[0196] The cellular receptor for Sindbis virus on mammalian cells is the high affinity laminin receptor, that is expressed mainly on cells of epithelial lineage, but is often overexpressed in many metastatic cancer cells like the Panc-1 pancreatic carcinoma line, and the SW620 colon adenocarcinoma cell line (Campo et al., (1992) Am. J. Pathol. 141, 1073-1083; Yow et al., (1988) Proc. Natl Acad Sci, 85, 6394-6398). In contrast, the rectum adenocarcinoma cell line SW1423 is known to express very low levels of high affinity laminin receptor mRNA (Yow et al., (1988) Proc. Natl Acad Sci, 85, 6394-6398), and is more than 4 order of magnitude more resistant to killing by PPSINDBIS-Ar339 than SW620 cells. These results (Table 25) demonstrate that cells that are tumorigenic and express high levels of the high affinity laminin receptor are more sensitive to killing by Sindbis Clone PPSINDBIS-Ar339 than other tumor or normal cells.

Example 26

VSV Killing of Tumorigenic and Non-Tumorigenic Cells in the Presence of Interferon.

[0197] In 96 well plates, tumorigenic KB and HT1080 cells (3 x 10⁴ cells per well) and non-tumorigenic WISH cells (2.5 x 10⁴ cells per well) were seeded in the presence of serially diluted interferon- α ranging from 2800 to 22 Units/ml and allowed to incubate for 24 hours at 37°C. The cells were then infected with vesicular stomatitis virus (VSV, Indiana strain) at an moi of 10. Controls were included for cells without interferon, and cells without interferon or virus. The cells were incubated at 37° for 24 hours. Cytotoxicity was quantified by using a colorimetric MTT (2-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Cell Titer 96, catalog #G4000, Promega Corporation, Madison WI 53711) monitored at 570 nm, that detects mitochondrial enzyme activity (Mosman, T., 1983, J. Immunol. Methods 65:55). The viability in the virus treated wells was expressed as a percent of the activity in control wells not receiving virus.

Table 26. Comparison of the Cell Killing Activity of VSV in Cells Treated with Exogenous Interferon.

	Percent Viable Cells		
	WISH	HT1080	KB
100 U/ml IFN	50	6	0
1000 U/ml IFN	95	20	12

[0198] These results (Table 26) demonstrate that VSV is able to selectively kill tumor cells deficient in interferon responsiveness (see Example 27). WISH cells (human amnion cells) are a well established cell line for the use in interferon bioassays because of their ability to respond efficiently to interferons.

Example 27

Interferon Responsiveness in Cells Sensitive or Resistant to Killing by PPMK107.

[0199] Individual cell lines were grown to near confluence in 96 well microtiter plates and treated with between 5 and 5000 U/ml of IFN α A for 24 hours. The cultures were then infected with PPMK 107 at an moi of 1.0 and cultured for an additional 24 hours. Following chemical fixation, the amount of viral expression was quantified by immunohistochemistry using a soluble indicator dye. The amount of virus growth is represented as the percent of P antigen expressed relative to control cells untreated with interferon (Figure 5). In this assay, interferon responsive cells manifest at least a 50%

decrease in the viral antigen in response to interferon. Cells in Figure 5 that are sensitive to PPMK107 are indicated by the solid lines; cells less sensitive are indicated by the dashed lines.

[0200] The results of this experiment show a strong correlation between the resistance of the cell line to the antiviral effects of exogenous interferon and the relative sensitivity of the cell to killing by PPMK107 (indicated by the IC₅₀ value shown in parentheses next to the cell line name in the graph legend, see Figure 5). For example, following pretreatment with 5 U/ml of interferon, 6 of 7 (86%) cell lines nonresponsive to interferon are sensitive to killing by PPMK107; when pretreated with 500 U/ml of interferon, all (4 of 4) of the nonresponsive cell lines are sensitive to killing by PPMK107. The data above also present an example of a screening assay to identify candidate cells that are likely to be sensitive to killing by PPMK107 or other interferon-sensitive viruses. For example, infected cells expressing significant (e.g., more than 50% of controls) viral antigen following pretreatment with exogenous interferon would be considered interferon deficient and thereby sensitive to viral oncolysis.

[0201] The foregoing is intended as illustrative of the present invention but not limiting. Numerous variations and modifications may be effected without departing from the true scope of the invention.

Claims

1. Use of an interferon-sensitive, replication-competent clonal RNA virus for the manufacture of a medicament for treating a neoplasm in a mammal.
2. Use according to Claim 1 wherein said RNA virus replicates at least 100-fold less in the presence of interferon compared to in the absence of interferon; preferably at least 1000-fold less in the presence of interferon compared to in the absence of interferon.
3. Use according to Claim 1 wherein said medicament is a systemic formulation.
4. Use according to Claim 1 wherein said neoplasm is a cancer.
5. Use according to Claim 1 wherein said mammal is a human.
6. Use according to Claim 1 wherein said clonal virus is plaque purified.
7. Use according to Claim 1 wherein said clonal virus is of recombinant clonal origin.
8. Use according to Claim 1 wherein said RNA virus is a Paramyxovirus.
9. Use according to Claim 8 wherein said Paramyxovirus is purified to a level of at least 2×10^9 PFU per mg of protein; preferably to a level of at least 1×10^{10} PFU per mg of protein; more preferably to a level of at least 6×10^{10} PFU per mg of protein.
10. Use according to Claim 8 wherein said Paramyxovirus is purified to a level in which the particle per PFU ratio is no greater than 5; preferably to a level in which the particle per PFU ratio is no greater than 3; more preferably to a level in which the particle per PFU ratio is no greater than 1.2.
11. Use according to Claim 8 wherein said Paramyxovirus is selected from the group consisting of avian paramyxovirus type 2, NDV, mumps virus, and human parainfluenza virus.
12. Use according to Claim 1 wherein said neoplasm is a cancer selected from the group consisting of lung, colon, prostate, breast, and brain cancer.
13. Use according to Claim 1 wherein said neoplasm is a solid tumor.
14. Use according to Claim 12 wherein said brain cancer is a glioblastoma.
15. Use according to Claim 1 wherein said virus contains a gene encoding interferon to permit the viral expression of interferon, or a gene encoding a pro-drug activating enzyme.
16. Use according to Claim 1, wherein the medicament is suitable for administration in combination with IFN, which is

administered before, during or after administration of said medicament.

17. Use according to Claim 16 wherein said interferon is selected from the group consisting of α -IFN, β -IFN, ω -IFN, γ -IFN, and synthetic consensus forms of IFN.
18. Use according to Claim 1, wherein the medicament is suitable for administration in combination with a tyrosine kinase inhibitor which is administered before, during or after administration of said medicament.
19. Use according to Claim 1, wherein the medicament is suitable for administration in combination with a compound selected from the group consisting of a purine nucleoside analog, tyrosine kinase inhibitor, cimetidine, and mitochondrial inhibitor.
20. Use according to Claim 1, wherein the medicament is suitable for administration in combination with a chemotherapeutic agent which is administered before, during or after administration of said medicament.
21. Use according to Claim 1, wherein the medicament is suitable for administration in combination with a cytokine or an immunosuppressant which is administered before, during or after administration of said virus.
22. Use according to Claim 1, wherein the medicament is suitable for administration in combination with a viral replication controlling amount of a compound selected from the group consisting of IFN, ribavirin, acyclovir, and ganciclovir.
23. Use according to Claim 1, wherein said medicament is an intravenous or intratumoral formulation.
24. Use of an interferon-sensitive clonal virus, selected from the group consisting of (1) RNA viruses; (2) Hepadenavirus; (3) Parvovirus; (4) Papovavirus; (5) Poxvirus; and (6) Iridovirus, in the manufacture of a medicament for treating a neoplasm which is at least 1 centimeter in size in a mammal.
25. Use according to Claim 24, wherein said neoplasm is at least 300 mm³ in volume.
26. Use according to Claim 24, wherein said RNA virus is a Paramyxovirus, preferably NDV.
27. Use according to Claim 24, wherein said mammal is a human.
28. Use according to Claim 24, wherein said medicament is an intravenous or intratumoral formulation.
29. Use according to Claim 24, wherein said paramyxovirus is purified to a level of at least 2 x 10⁹ PFU per mg protein.
30. Use according to Claim 26, wherein said NDV is mesogenic.
31. Use according to Claim 24, wherein said neoplasm is cancerous.
32. Use of a therapeutically effective amount of an interferon-sensitive clonal RNA virus in the manufacture of a medicament for treating a tumor in a mammal wherein said virus is cytotoxic to said tumor, and wherein said mammal has a tumor burden comprising at least 1.5% of the total body weight of said mammal.
33. Use according to Claim 32, wherein said tumor does not respond to chemotherapy.
34. Use according to Claim 1, wherein said virus is selected from the group consisting of the Newcastle disease virus strain MK107, Newcastle disease virus strain NJ Roakin, Sindbis virus, and Vesicular stomatitis virus.
35. Use of an interferon sensitive clonal virus selected from the group consisting of the Newcastle disease virus strain MK107, Newcastle disease virus strain NJ Roakin, Sindbis virus, and Vesicular stomatitis virus for the manufacture of a medicament for treating a neoplasm in a mammal.
36. Use according to Claim 1, wherein the treatment comprises administering said medicament as more than one dose.
37. Use according to Claim 36, wherein the first dose is a desensitizing dose.

38. Use according to Claim 37, wherein said first dose is administered intravenously and a subsequent dose administered intravenously.
- 5 39. Use according to Claim 37, wherein said first dose is administered intravenously and a subsequent dose administered intraperitoneally.
40. Use according to Claim 37, wherein said first dose is administered intravenously and a subsequent dose administered intra-arterially.
- 10 41. Use of an interferon-sensitive, replication competent clonal virus which binds to a receptor present in a mammal for the manufacture of a medicament for treating a neoplasm in a mammal, wherein the treatment further comprises subjecting a sample from said mammal to an immunoassay to detect the presence of the virus receptor.
- 15 42. Use according to Claim 1, wherein the treatment comprises administration of the medicament over the course of at least 4 minutes.

Patentansprüche

- 20 1. Verwendung eines Interferon-empfindlichen replikationskompetenten klonalen RNA-Virus zur Herstellung eines Medikaments zur Behandlung eines Neoplasmas in einem Säuger.
- 25 2. Verwendung nach Anspruch 1, wobei sich das Virus wenigstens 100-fach weniger in Gegenwart von Interferon repliziert, verglichen mit der Abwesenheit von Interferon; vorzugsweise wenigstens 1000-mal weniger in Gegenwart von Interferon, verglichen mit der Abwesenheit von Interferon.
- 30 3. Verwendung nach Anspruch 1, wobei das Medikament eine systemische Formulierung ist.
4. Verwendung nach Anspruch 1, wobei das Neoplasma ein Krebs ist.
5. Verwendung nach Anspruch 1, wobei der Säuger ein Mensch ist.
6. Verwendung nach Anspruch 1, wobei das klonale Virus plaquegereinigt ist.
- 35 7. Verwendung nach Anspruch 1, wobei das klonale Virus einen rekombinanten klonalen Ursprung hat.
8. Verwendung nach Anspruch 1, wobei das RNA-Virus ein Paramyxovirus ist.
- 40 9. Verwendung nach Anspruch 8, wobei das Paramyxovirus auf ein Niveau von wenigstens 2×10^9 PFU pro mg Protein gereinigt wird; vorzugsweise auf ein Niveau von wenigstens 1×10^{10} PFU pro mg Protein; besonders bevorzugt auf ein Niveau von wenigstens 6×10^{10} PFU pro mg Protein.
- 45 10. Verwendung nach Anspruch 8, wobei das Paramyxovirus auf ein Niveau gereinigt wird, in welchem das Partikel zu PFU-Verhältnis nicht größer als 5 ist; vorzugsweise auf ein Niveau, in welchem das Partikel zu PFU-Verhältnis nicht größer als 3 ist; besonders bevorzugt auf ein Niveau, in welchem das Partikel zu PFU-Verhältnis nicht größer als 1,2 ist.
- 50 11. Verwendung nach Anspruch 8, wobei das Paramyxovirus ausgewählt wird aus der Gruppe bestehend aus dem aviären Paramyxovirus Typ 2, NDV, Mumpsvirus und humanem Parainfluenzavirus.
12. Verwendung nach Anspruch 1, wobei das Neoplasma ein Krebs ist, ausgewählt aus der Gruppe bestehend aus Lungen-, Colon-, Prostata-, Brust- und Gehirnkrebs.
- 55 13. Verwendung nach Anspruch 1, wobei das Neoplasma ein solider Tumor ist.
14. Verwendung nach Anspruch 12, wobei der Gehirnkrebs ein Glioblastom ist.
15. Verwendung nach Anspruch 1, wobei das Virus ein Gel enthält, welches Interferon codiert, um die virale Expression

von Interferon zu erlauben, oder ein Gen, welches ein Prodrug-aktivierendes Enzym codiert.

16. Verwendung nach Anspruch 1, wobei das Medikament geeignet ist zur Verabreichung in Kombination mit IFN, welches vor, während oder nach Verabreichung des Medikaments verabreicht wird.
17. Verwendung nach Anspruch 16, wobei das Interferon ausgewählt wird aus der Gruppe bestehend aus α -IFN, β -IFN, ω -IFN, γ -IFN und synthetischen Consensusformen von IFN.
18. Verwendung nach Anspruch 1, wobei das Medikament geeignet ist zur Verabreichung in Kombination mit einem Tyrosinkinaseinhibitor, welcher vor, während oder nach Verabreichung des Medikaments verabreicht wird.
19. Verwendung nach Anspruch 1, wobei das Medikament geeignet ist zur Verabreichung in Kombination mit einer Verbindung, welche ausgewählt wird aus der Gruppe bestehend aus einem Purinnucleosidanalogon, einem Tyrosinkinaseinhibitor, Cimetidin und einem mitochondrialen Inhibitor.
20. Verwendung nach Anspruch 1, wobei das Medikament geeignet ist zur Verabreichung in Kombination mit einem chemotherapeutischen Mittel, welches vor, während oder nach Verabreichung des Medikaments verabreicht wird.
21. Verwendung nach Anspruch 1, wobei das Medikament geeignet ist zur Verabreichung in Kombination mit einem Cytokin oder einem immunsuppressiven Mittel, welches vor, während oder nach Verabreichung des Virus verabreicht wird.
22. Verwendung nach Anspruch 1, wobei das Medikament geeignet ist zur Verabreichung in Kombination mit einer die virale Replikation steuernden Menge einer Verbindung, welche ausgewählt wird aus der Gruppe bestehend aus IFN, Ribavirin, Aciclovir und Ganciclovir.
23. Verwendung nach Anspruch 1, wobei das Medikament als intravenöse oder intratumorale Formulierung vorliegt.
24. Verwendung eines Interferon-empfindlichen klonalen Virus, ausgewählt aus der Gruppe bestehend aus (1) RNA-Viren; (2) Hepadenavirus; (3) Parvovirus; (4) Papovavirus; (5) Pockenvirus; und (6) Iridovirus, bei der Herstellung eines Medikaments zur Behandlung eines in einem Säuger wenigstens 1 cm großen Neoplasmas.
25. Verwendung nach Anspruch 24, wobei das Neoplasma ein Volumen von wenigstens 300 mm³ aufweist.
26. Verwendung nach Anspruch 24, wobei das RNA-Virus ein Paramyxovirus ist, vorzugsweise NDV.
27. Verwendung nach Anspruch 24, wobei der Säuger ein Mensch ist.
28. Verwendung nach Anspruch 24, wobei das Medikament als intravenöse oder intratumorale Formulierung vorliegt.
29. Verwendung nach Anspruch 24, wobei das Paramyxovirus auf ein Niveau von wenigstens 2 x 10⁹ PFU pro mg Protein gereinigt ist.
30. Verwendung nach Anspruch 26, wobei das NDV mesogen ist.
31. Verwendung nach Anspruch 24, wobei das Neoplasma krebsartig ist.
32. Verwendung einer therapeutisch wirksamen Menge eines Interferon-empfindlichen klonalen RNA-Virus zur Herstellung eines Medikaments zur Behandlung eines Tumors in einem Säuger, wobei das Virus zellzerstörend für den Tumor ist und wobei der Säuger einer Tumorbelastrung unterliegt, welche wenigstens 1,5 % des gesamten Körpergewichts des Säugers beträgt.
33. Verwendung nach Anspruch 32, wobei der Tumor nicht auf Chemotherapie anspricht.
34. Verwendung nach Anspruch 1, wobei das Virus ausgewählt wird aus der Gruppe bestehend aus dem Newcastle disease-Virusstamm MK107, Newcastle disease-Virusstamm NJ Roakin, Sindbisvirus und vesikulärem Stomatitis-virus.

35. Verwendung eines Interferon-empfindlichen klonalen Virus, ausgewählt aus der Gruppe bestehend aus dem Newcastle disease-Virusstamm MK 107, Newcastle disease-Virusstamm NJ Roakin, Sindbisvirus und vesikulärem Stomatitisvirus zur Herstellung eines Medikaments zur Behandlung eines Neoplasmas in einem Säuger.
- 5 36. Verwendung nach Anspruch 1, wobei die Behandlung die Verabreichung des Medikaments in mehr als einer Dosis umfasst.
37. Verwendung nach Anspruch 36, wobei die erste Dosis eine desensibilisierende Dosis ist.
- 10 38. Verwendung nach Anspruch 37, wobei die erste Dosis intravenös verabreicht wird und eine Folgedosis intravenös verabreicht wird.
39. Verwendung nach Anspruch 37, wobei die erste Dosis intravenös verabreicht wird und eine Folgedosis intraperitoneal verabreicht wird.
- 15 40. Verwendung nach Anspruch 37, wobei die erste Dosis intravenös verabreicht wird und eine Folgedosis intraarteriell verabreicht wird.
41. Verwendung eines Interferon-empfindlichen replikationskompetenten klonalen Virus, welcher an einen Rezeptor bindet, der in einem Säuger vorliegt, zur Herstellung eines Medikaments zur Behandlung eines Neoplasmas in einem Säuger, wobei die Behandlung ferner das Untersuchen einer Probe aus dem Säuger mittels eines Immunnassays umfasst, um das Vorliegen des Virusrezeptors zu erfassen.
- 20 42. Verwendung nach Anspruch 1, wobei die Behandlung die Verabreichung des Medikaments über den Verlauf von wenigstens 4 Minuten umfasst.
- 25

Revendications

- 30 1. Utilisation d'un virus à ARN clonal compétent pour la réplication, sensible à l'interféron pour la fabrication d'un médicament destiné au traitement d'un néoplasme chez un mammifère.
2. Utilisation selon la revendication 1, où ledit virus à ARN se réplique au moins 100 fois moins en présence d'interféron par comparaison à en l'absence d'interféron ; de préférence au moins 1000 fois moins en présence d'interféron par comparaison à en l'absence d'interféron.
- 35 3. Utilisation selon la revendication 1, où ledit médicament est une formulation systémique.
4. Utilisation selon la revendication 1, où ledit néoplasme est un cancer.
- 40 5. Utilisation selon la revendication 1, où ledit mammifère est un homme.
6. Utilisation selon la revendication 1, où ledit virus clonal est purifié par plage.
- 45 7. Utilisation selon la revendication 1, où ledit virus clonal est d'origine clonale recombinante.
8. Utilisation selon la revendication 1, où ledit virus à ARN est un Paramyxovirus.
- 50 9. Utilisation selon la revendication 8, où ledit Paramyxovirus est purifié jusqu'à un taux d'au moins 2×10^9 PFU par mg de protéine ; de préférence, jusqu'à un taux d'au moins 1×10^{10} PFU par mg de protéine ; de manière davantage préférée, jusqu'à un taux d'au moins 6×10^9 PFU par mg de protéine.
- 55 10. Utilisation selon la revendication 8, où ledit Paramyxovirus est purifié jusqu'à un taux dans lequel le rapport de particules par PFU n'est pas supérieur à 5 ; de préférence, jusqu'à un taux dans lequel le rapport de particules par PFU n'est pas supérieur à 3 ; de manière davantage préférée, jusqu'à un taux dans lequel le rapport de particules par PFU n'est pas supérieur à 1,2.
11. Utilisation selon la revendication 8, où ledit Paramyxovirus est choisi dans le groupe constitué du paramyxovirus

aviaire de type 2, du NDV, du virus des oreillons et du virus parainfluenza humain.

12. Utilisation selon la revendication 1, où ledit néoplasme est un cancer choisi dans le groupe constitué d'un cancer du poumon, du côlon, de la prostate, du sein et du cerveau.
13. Utilisation selon la revendication 1, où ledit néoplasme est une tumeur solide.
14. Utilisation selon la revendication 12, où ledit cancer du cerveau est un glioblastome.
15. Utilisation selon la revendication 1, où ledit virus contient un gène codant l'interféron pour permettre l'expression virale de l'interféron, ou un gène codant une enzyme activant un précurseur.
16. Utilisation selon la revendication 1, où le médicament est approprié pour une administration en combinaison avec de l'IFN qui est administré avant, pendant ou après l'administration dudit médicament.
17. Utilisation selon la revendication 16, où ledit interféron est choisi dans le groupe constitué de l'IFN α , l'IFN β , l'IFN ω , l'IFN γ et de formes consensus synthétiques d'IFN.
18. Utilisation selon la revendication 1, où le médicament est approprié pour une administration en combinaison avec un inhibiteur de tyrosine kinase qui est administré avant, pendant ou après l'administration dudit médicament.
19. Utilisation selon la revendication 1, où le médicament est approprié pour une administration en combinaison avec un composé choisi dans le groupe constitué d'un analogue nucléosidique de la purine, d'un inhibiteur de tyrosine kinase, de cimétidine et d'un inhibiteur mitochondrial.
20. Utilisation selon la revendication 1, où le médicament est approprié pour une administration en combinaison avec un agent chimiothérapeutique qui est administré avant, pendant ou après l'administration dudit médicament.
21. Utilisation selon la revendication 1, où le médicament est approprié pour une administration en combinaison avec une cytokine ou un immunosuppresseur qui est administré avant, pendant ou après l'administration dudit virus.
22. Utilisation selon la revendication 1, où le médicament est approprié pour une administration en combinaison avec une quantité contrôlant la réplication virale d'un composé choisi dans le groupe constitué d'IFN, de ribavirine, d'aciclovir et de ganciclovir.
23. Utilisation selon la revendication 1, où ledit médicament est une formulation intraveineuse ou intratumorale.
24. Utilisation d'un virus cloné sensible à l'interféron, choisi dans le groupe constitué de (1) virus à ARN ; (2) Hépadnavirus ; (3) Parvovirus ; (4) Papovavirus ; (5) Poxvirus ; et (6) Iridovirus, dans la fabrication d'un médicament destiné au traitement d'un néoplasme qui a une taille d'au moins de 1 cm chez un mammifère.
25. Utilisation selon la revendication 24, où ledit néoplasme a un volume d'au moins 300 mm³.
26. Utilisation selon la revendication 24, où ledit virus à ARN est un Paramyxovirus, de préférence le NDV.
27. Utilisation selon la revendication 24, où ledit mammifère est un homme.
28. Utilisation selon la revendication 24, où ledit médicament est une formulation intraveineuse ou intratumorale.
29. Utilisation selon la revendication 24, où ledit paramyxovirus est purifié jusqu'à un taux d'au moins 2 x 10⁹ PFU par mg de protéine.
30. Utilisation selon la revendication 26, où ledit NDV est mésogène.
31. Utilisation selon la revendication 24, où ledit néoplasme est cancéreux.
32. Utilisation d'une quantité thérapeutiquement efficace d'un virus à ARN clonal sensible à l'interféron dans la fabrication d'un médicament destiné au traitement d'une tumeur chez un mammifère où ledit virus est cytocide envers ladite

EP 1 032 269 B1

tumeur, et où ledit mammifère a une charge tumorale composant au moins 1,5 % du poids corporel total dudit mammifère.

- 5
33. Utilisation selon la revendication 32, où ladite tumeur ne répond pas à la chimiothérapie.
- 10
34. Utilisation selon la revendication 1, où ledit virus est choisi dans le groupe constitué de la souche MK 107 du virus de la maladie de Newcastle, de la souche NJ Roakin du virus de la maladie de Newcastle, du virus Sindbis et du virus de la stomatite vésiculaire.
- 15
35. Utilisation d'un virus clonal sensible à l'interféron choisi dans le groupe constitué de la souche MK 107 du virus de la maladie de Newcastle, de la souche NJ Roakin du virus de la maladie de Newcastle, du virus Sindbis et du virus de la stomatite vésiculaire, pour la fabrication d'un médicament destiné au traitement d'un néoplasme chez un mammifère.
- 20
36. Utilisation selon la revendication 1, où le traitement comprend l'administration dudit médicament sous la forme de plus d'une dose.
- 25
37. Utilisation selon la revendication 36, où la première dose est une dose désensibilisante.
- 30
38. Utilisation selon la revendication 37, où ladite première dose est administrée par voie intraveineuse et une dose ultérieure est administrée par voie intraveineuse.
- 35
39. Utilisation selon la revendication 37, où ladite première dose est administrée par voie intraveineuse et une dose ultérieure est administrée par voie intrapéritonéale.
- 40
40. Utilisation selon la revendication 37, où ladite première dose est administrée par voie intraveineuse et une dose ultérieure est administrée par voie intra-artérielle.
- 45
41. Utilisation d'un virus clonal compétent pour la réplication, sensible à l'interféron qui se lie à un récepteur présent chez un mammifère pour la fabrication d'un médicament destiné au traitement d'un néoplasme chez un mammifère, où le traitement comprend en outre la soumission d'un échantillon provenant dudit mammifère à un test immunologique pour détecter la présence du récepteur viral.
- 50
42. Utilisation selon la revendication 1, où le traitement comprend l'administration du médicament sur une période d'au moins 4 minutes.
- 55


Fig. 1

Fig. 2






Fig. 3

Fig. 4





Fig. 5

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 9425627 A [0010]
- WO 9626285 A [0025]
- CN 1054192 A [0026]

Non-patent literature cited in the description

- HILLARD STANLEY. *Cancer Treat. Reports*, January 1977, vol. 61 (1), 29-36 [0002]
- TANNOCK. *Cancer Research*, December 1982, vol. 42, 4921-4926 [0002]
- SMITH et al. *Cancer*, 1956, vol. 9, 1211 [0003]
- HOLZAEPEL et al. *Cancer*, 1957, vol. 10, 557 [0003]
- TAYLOR et al. *J. Natl. Cancer Inst.*, 1970, vol. 44, 515 [0003]
- SHINGU et al. *J. General Virology*, 1991, vol. 72, 2031 [0003]
- SUSKIND et al. *PSEBM*, 1957, vol. 94, 309 [0003]
- RUKAVISHNIKOVA et al. *Acta Virol.*, 1976, vol. 20, 387 [0003]
- DEPACE, N.G. *Ginecologia*, 1912, vol. 9, 82-88 [0004]
- SALMON, P ; BAIX. *Compt. Rend. Soc. Biol.*, 1922, vol. 86, 819-820 [0004]
- PASQUINUCCI, G. *Lancet*, 1971, vol. 1, 136 [0004]
- GROSS, S. *Lancet*, 1971, vol. 1, 397-398 [0004]
- BLUMING, A.Z ; ZIEGLER, J.L. *Lancet*, 1971, vol. 2, 105-106 [0004]
- ASADA. *Cancer*, 1994, vol. 34, 1907-1928 [0004]
- MURPHY A ; KINGSBURY DW. *Virology*. Raven Press, 1990, 9-35 [0005]
- CSATARY, L.K. *Lancet*, 1971, vol. 2, 825 [0008]
- CASSEL, W.A ; GARRETT, R.E. *Cancer*, 1965, vol. 18, 863-868 [0008]
- MURRAY, D.R ; CASSEL, W.A ; TORBIN, A.H ; OLKOWSKI, Z.L ; MOORE, M.E. *Cancer*, 1977, vol. 40, 680 [0008]
- CASSEL, W.A ; MURRAY, D.R ; PHILLIPS, H.S. *Cancer*, 1983, vol. 52, 856 [0008]
- BOHLE, W ; SCHLAG, P.J ; LIEBRICH, W ; HOHENBERGER, P ; MANASTERSKI, M ; MILLER, P ; SCHIRRMACHER, V. *Cancer*, 1990, vol. 66, 1517-1523 [0008]
- RODRIGUEZ, R et al. *Cancer Res.*, 1997, vol. 57, 2559-2563 [0009]
- BISCHOFF, JR et al. *Science*, 1996, vol. 274, 373-376 [0009]
- ZHANG, WW et al. *Cancer gene therapy*, 1994, vol. 1, 5-13 [0009]
- MINETA, T et al. *Cancer Res.*, 1994, vol. 54, 3963-3966 [0009]
- ZHANG et al. *Proc. Natl. Acad. Sci., USA*, 1996, vol. 93, 4513-4518 [0013]
- ZHANG et al. *Cancer Gene Ther.*, 1996, vol. 3, 31-38 [0014]
- PEPLINSKI et al. *Ann. Surg. Oncol.*, 1996, vol. 3, 15-23 [0015]
- GASTL et al. *Cancer Res.*, 1992, vol. 52, 6229-6236 [0016]
- RESTIFO et al. *J. Exp. Med.*, 1992, vol. 175, 1423-1431 [0017]
- HOWARD et al. *Ann. NY Acad. Sci.*, 1994, vol. 716, 167-187 [0018]
- KIRCHNER et al. *World J. Urol.*, 1995, vol. 13, 171-173 [0019]
- TANAKA et al. *J. Immunother. Emphasis Tumor Immunol.*, 1994, vol. 16, 283-293 [0020]
- ARROYO et al. *Cancer Immunol. Immunother.*, 1990, vol. 31, 305-311 [0021]
- *Intervirology*, 1993, vol. 36/4, 193-214 [0023]
- *Proceedings of the American Association for Cancer Research Annual*, 1995, vol. 36, 439 [0024]
- *CHEMICAL ABSTRACTS*, 116:104333 [0026]
- *Nature*, 23 August 1969, vol. 223, 844-845 [0027]
- LORENCE, R et al. *J Natl Cancer Inst.*, 1994, vol. 86, 1228-1233 [0055]
- JOKLIK, W.K. *Interferons*, 1990, 383-410 [0057]
- *Virology*. Raven Press Ltd, 1995 [0057]
- *Biologic Therapy of Cancer*. J.B. Lippincott Company [0057]
- *Virology*. Raven Press Ltd [0057]
- KATZE, M.G. *Trends in Microbiol.*, 1995, vol. 3, 75-78 [0057]
- MAHESHWARI R.K. *Biochem. Biophys. Res. Comm.*, 1983, vol. 17, 161-168 [0058]
- ZHANG et al. *Cancer Gene Therapy*, 1996, vol. 3, 31-38 [0059]
- TANAKA et al. *Cell*, 1994, vol. 77, 829-839 [0059]
- BARBER, GN. *Proc. Natl. Acad. Sci USA*, 1994, vol. 91, 4278-4282 [0059]

- JAMES, CD et al. *Cancer Res.*, 1991, vol. 51, 1684-1688 [0059]
- PETRICIOIN, E et al. *Mol. Cell. Bio.*, 1994, vol. 14, 1477-1486 [0059]
- XU, B et al. *Blood*, 1994, vol. 84, 1942-1949 [0059]
- LINGE, C et al. *Cancer Res.*, 1995, vol. 55, 4099-4104 [0059]
- HAINES, G.K et al. *Virchows Arch B Cell Pathol*, 1993, vol. 63, 289-95 [0060]
- BARBER GN et al. *Proc Natl Acad Sci USA*, 1994, vol. 91, 4278-4282 [0060]
- KORTH MJ et al. *Gene*, 1996, vol. 170, 181-188 [0060]
- KALVAKOLANU, DVR ; SEN, G.C. *Proc Natl Acad Sci USA*, 1993, vol. 90, 3167-3171 [0060]
- HANSON ; BRANDLY. *Science*, 1955, vol. 122, 156-157 [0078]
- DARDIRI et al. *Am. J. Vet. Res.*, 1961, 918-920 [0078]
- SCHLOER ; HANSON. *J. Virol*, 1968, vol. 2, 40-47 [0078]
- MAASSAB et al. *Vaccines*, Philadelphia. W.B. Saunders Co, 1994, 78-801 [0080]
- WANG et al. *J Virol*, 1992, vol. 66, 4992-5001 [0101]
- CAMPO et al. *Am J Pathol*, 1992, vol. 141, 107301983 [0101]
- YOW et al. *Proc. Natl Acad Sci*, 1988, vol. 85, 6394-6398 [0101] [0101] [0196] [0196]
- BLAESE RM et al. *Eur. J. Cancer*, 1994, vol. 30A, 1190-1193 [0103]
- MEBASTSION et al. *Cell*, 1997, vol. 90, 841-847 [0103]
- SCHNELL MJ et al. *Cell*, 1997, vol. 90, 849-857 [0103]
- WANG et al. *J. Virol*, 1992, vol. 66, 4992-5001 [0106]
- HAND et al. *Cancer Res.*, 1985, vol. 45, 2713-2719 [0106]
- IMANI F ; JACOBS B. *Proc Natl Acad Sci USA*, 1988, vol. 85, 7887-7891 [0113]
- BEATTIE E et al. *Virology*, 1991, vol. 183, 419 [0113]
- BEATTIE E et al. *Virus Genes*, 1996, vol. 12, 89-94 [0113]
- SYMONS JA et al. *Cell*, 1995, vol. 81, 551-560 [0113]
- MATHEWS MB ; SHENK T. *J Virol*, 1991, vol. 64, 5657-5662 [0113]
- CHOU J et al. *Proc Natl Acad Sci USA*, 1996, vol. 92, 10516-10520 [0113]
- SPRIGGS DR ; FIELDS BN. *Nature*, vol. 297, 68-70 [0113]
- CLARK HF. *J Infect Dis*, 1988, vol. 158, 570-587 [0113]
- BULLER RML et al. *Virology*, 1988, vol. 164, 182 [0113]
- BULLER RML et al. *Nature*, 1985, vol. 317, 813-815 [0113]
- HUGHES SJ et al. *J Biol Chem*, 1991, vol. 266, 20103-20109 [0113]
- KERR SM et al. *EMBO J*, 1991, vol. 10, 4343-4350 [0113]
- CHILD SJ. *Virology*, 1990, vol. 174, 625-629 [0113]
- PERKUS ME et al. *Virology*, 1991, vol. 180, 406-410 [0113]
- TAKAFUGI ET et al. *J Infect Dis*, 1979, vol. 140, 48-53 [0113]
- FIELD HJ ; WILDY P. *J Hyg*, 1978, vol. 81, 267-277 [0113]
- GOLDSTEIN DJ ; WELLER SK. *Virology*, 1988, vol. 166, 41-51 [0113]
- CHOU J et al. *Proc Natl Acad Sci USA*, 1995, vol. 92, 10516-10520 [0113]
- MEIGNIER B et al. *J Infect Dis*, 1988, vol. 162, 313-322 [0113]
- COTRAN et al. *Robbins Pathological Basis of Diseases*. WB Saunders, 1989, 252 [0115]
- TAKAHASHI et al. *Cancer Res.*, 1991, vol. 51, 2366-2372 [0124]
- Current Medical Diagnosis and Treatment. Appleton & Lange, 1997, 78-94 [0130]
- RODRIQUES, R et al. *Cancer Res*, 1997, vol. 57, 2559-2563 [0130]
- BISCHOFF, J.R et al. *Science*, 1996, vol. 274, 373-376 [0130]
- MINETA, T et al. *Nature Medicine*, 1995, vol. 1, 938-943 [0130]
- ZHANG, WW et al. *Cancer Gene Therapy*, 1994, vol. 1, 5-13 [0130]
- SREEVALSOUN, T. *Biologic Therapy of Cancer*. J.B. Lippincott Company, 1995, 347-364 [0131]
- FOY, T.M et al. *J. Exp. Med.*, 1993, vol. 178, 1567-1575 [0132]
- MACHIDA, H. *Microbiol. Immunol.*, 1979, vol. 23, 643-650 [0133]
- MOSMAN, T. *J. Immunol. Methods*, 1983, vol. 65, 55 [0139] [0189] [0191] [0195] [0197]
- FAABERG KS ; PEEPLES, ME. *J Virol*, 1988, vol. 62, 586 [0174]
- BRATT, MA ; RUBIN, H. *Virology*, 1967, vol. 33, 598-608 [0174]
- CAMPO et al. *Am. J. Pathol*, 1992, vol. 141, 1073-1083 [0196]